<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003703.pub3" GROUP_ID="ANAESTH" ID="106401110215472643" MERGED_FROM="" MODIFIED="2016-04-22 16:56:17 +0100" MODIFIED_BY="Jane Cracknell" REVIEW_NO="035" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-04-22 16:56:17 +0100" MODIFIED_BY="Jane Cracknell">
<TITLE>Selenium supplementation for critically ill adults</TITLE>
<CONTACT MODIFIED="2016-04-22 16:56:17 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1403241137508671148788714740679" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mikkel</FIRST_NAME><LAST_NAME>Allingstrup</LAST_NAME><EMAIL_1>mikkel.allingstrup@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Køge Sygehus, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-04-22 16:56:17 +0100" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1403241137508671148788714740679" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mikkel</FIRST_NAME><LAST_NAME>Allingstrup</LAST_NAME><EMAIL_1>mikkel.allingstrup@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Køge Sygehus, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="18607" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Afshari</LAST_NAME><POSITION>Consultant Pediatric anesthetist and Intensivist</POSITION><EMAIL_1>arriba.a@gmail.com</EMAIL_1><EMAIL_2>afshari@rocketmail.com</EMAIL_2><MOBILE_PHONE>004551948186</MOBILE_PHONE><ADDRESS><DEPARTMENT>Juliane Marie Centre - Anaesthesia and Surgical Clinic Department 4013</DEPARTMENT><ORGANISATION>Rigshospitalet, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-12-12 18:08:26 +0000" MODIFIED_BY="Jane Cracknell">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="5" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-22 16:54:18 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-22 16:54:18 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="22" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Typo corrected. The word significant was missing from one sentence in the plain language summary. The sentence has beedn corrected to read: ' Thirteen trials of intravenous sodium selenite showed a statistically significant effect on death.'</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-22 16:52:52 +0100" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-22 16:52:52 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="25" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>The previous review authors (Avenell A, Noble DW, Barr J, Engelhardt T) decided not to update this Cochrane review. Two new review authors have updated this review (Allingstrup M, Afshari A).</P>
<P>The conclusions have not changed in this updated Cochrane review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-22 16:52:49 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="25" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>We searched the databases up to 21 May 2014. We included six new trials of selenium (2084 participants) in this review update (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>). This review now includes 16 studies in total.</P>
<P>We updated the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>, included full 'Risk of bias' tables and 'Summary of findings' tables. We used trial sequential analysis.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="17" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Three new trials are included. Two of these were previously classified as ongoing trials (Mishra 2005, Angstwurm 2006). The conclusions of the review are unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-23 13:30:37 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="16" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Search reran</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-07 16:00:47 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="16" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Search strategies reran until 17th August 2007</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-12-09 17:49:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<INTERNAL_SOURCES MODIFIED="2014-12-09 17:49:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<SOURCE MODIFIED="2014-12-09 17:46:44 +0000" MODIFIED_BY="Mikkel Allingstrup">
<NAME>Herlev Hospital, University of Copenhagen</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Department of Anaesthesia and Intensive Care</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-12-09 17:49:36 +0000" MODIFIED_BY="Mikkel Allingstrup">
<NAME>Rigshospitalet, University of Copenhagen</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Anaesthesia and Surgical Clinic Department 4013</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-22 16:51:57 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2016-04-22 16:51:30 +0100" MODIFIED_BY="Jane Cracknell">
<TITLE>Selenium supplements for adults who are critically ill</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-22 16:51:30 +0100" MODIFIED_BY="Jane Cracknell">
<P>Selenium is a mineral that is essential to health. It has an important role in defence against tissue damage and disease. Improving selenium status could help protect adults with serious illness.</P>
<P>In this updated review, Cochrane researchers assessed the effects of additional selenium supplementation for adults recovering from critical illness. We investigated whether the number of people who died changed by giving a selenium supplement during their treatment. Also we checked the impact of such a strategy on the rate of infections and other diseases for these patients while in hospital. We also examined whether selenium affected the duration of respiratory assistance for patients on ventilators and the length of their stay in the intensive care unit and the hospital.</P>
<P>We included 16 trials with 2084 participants. Thirteen trials carried out tests with selenium while three trials examined selenium-containing compound ebselen. Overall quality of the included trials was poor, with little information on quality indicators. The results were limited and these trials involving selenium supplementation were mostly small. In most trials, there was a high risk of poor or even incorrect information. Thus the results must be interpreted with caution. The evidence is current to 21 May 2014.<BR/>
</P>
<P>Thirteen trials of intravenous sodium selenite showed a statistically significant effect on death. Three trials of the selenium-containing compound ebselen showed no effect on death. No effects on infections or secondary diseases were observed.<BR/>
</P>
<P>No clear evidence emerged for the benefits of selenium or ebselen supplementation for days on a respirator, length of intensive care unit stay, length of hospital stay or quality of life. Due to the quality of included trials, one must be cautious when interpreting the strength of the evidence in favour of selenium supplementation despite a statistically significant finding.</P>
<P>Overall, there was low quality evidence from the studies for the all results. Trials are required which overcome the statistical uncertainty of the reviewed studies, particularly in relation to sample size, design and outcomes.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-07-27 12:57:05 +0100" MODIFIED_BY="Jane Cracknell">
<ABS_BACKGROUND MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium is a trace mineral essential to health and has an important role in immunity, defence against tissue damage and thyroid function. Improving selenium status could help protect against overwhelming tissue damage and infection in critically ill adults. This Cochrane review was originally published in 2004 updated in 2007 and again 2015. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>The primary objective was to examine the effect of nutrition supplemented with selenium or ebselen on mortality in critically ill patients.</P>
<P>The secondary objective was to examine the relationship between selenium or ebselen supplementation and number of infections, duration of mechanical ventilation, length of intensive care unit stay and length of hospital stay.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this update, we searched the current issue of the Cochrane Central Register of Controlled Trials, the Cochrane Library (2014<I>, </I>Issue 5); MEDLINE (Ovid SP, to May 20, 2014), EMBASE (Ovid SP, to May 20, 2014), CAB, BIOSIS and CINAHL. We handsearched the reference lists of the newest reviews and cross-checked with our search in MEDLINE. We contacted the main authors of included studies to request any missed, unreported or ongoing studies. The latest search was performed up to 21 May 2014. The search is now from inception until 21 May 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted the trial investigators and authors in order to retrieve relevant and missing data.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-07-25 06:26:52 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Two review authors independently extracted data and we resolved any disagreements by discussion. Our primary outcome measure was all-cause mortality. We performed several subgroup and sensitivity analyses to assess the effects of selenium in critically ill patients. We presented pooled estimates of the effects of intervention as risk ratios (RRs) with 95% confidence intervals (CIs). We assessed the risk of bias through assessment of trial methodological components and the risk of random error through trial sequential analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-07-27 12:57:05 +0100" MODIFIED_BY="Jane Cracknell">
<P>We included six new RCTs in this review update. In total we included 16 RCTs (2084 participants) in this review. Most trials were at high risk of bias. The availability of outcome data was limited and trials involving selenium supplementation were, with the exception of one trial, small regarding sample size. Thus the results must be interpreted with caution.</P>
<P>Thirteen trials of intravenous sodium selenite showed a statistically significant reduction in overall mortality (RR 0.82, 95% CI 0.72 to 0.93, 1391 participants, <I>very low quality of evidence</I>). However, the overall point estimate on mortality is primarily influenced by trials of high risk of bias. Meta-analysis of three trials of ebselen had a RR of 0.83 (95% CI 0.52 to 1.34, 693 participants, <I>very low quality of evidence</I>).</P>
<P>Nine trials of intravenous sodium selenite were analysed for 28 days mortality with no statistically significant difference (RR 0.84, 95% CI 0.69 to 1.02, 1180 participants, <I>very low quality of evidence</I>) while three trials were analysed for 90 days mortality with similar findings (RR 0.96, 95% Cl 0.78 to 1.18, 614 participants, <I>very low quality of evidence</I>).</P>
<P>Two trials of ebselen were analysed for 90 days mortality and were not found to yield any benefit (RR 0.72, 95% Cl 0.42 to 1.22, 588 participants, <I>very low quality of evidence</I>).</P>
<P>For mortality among intensive care patients selenium supplementation failed to indicate any statistically significant advantage (RR 0.88, 95% CI 0.77 to 1.01, nine trials, 1168 participants, <I>very low quality of evidence</I>).</P>
<P>Six trials of intravenous sodium selenite found no statistically significant difference for participants developing infection (RR 0.96, 95% CI 0.75 to 1.23, 934 patients, <I>very low quality of evidence</I>). Similarly, three trials of ebselen provided data for participants developing infections (pyrexia, respiratory infections or meningitis) with no obvious benefit (RR 0.60, 95% CI 0.36 to 1.02, 685 participants, <I>very low quality of evidence</I>).</P>
<P>Our analyses showed no effect of selenium or ebselen on adverse events (Selenium: RR 1.03, 95% Cl 0.85 to 1.24; six trials, 925 participants ; Ebselen: RR 1.16, 95% CI 0.40 to 3.36; two trials, 588 participants, <I>very low quality of evidence</I>).</P>
<P>No clear evidence emerged in favour of selenium supplementation for outcomes such as number of days on a ventilator (mean difference (MD) -0.86, 95% CI -4.39 to 2.67, four trials, 191 participants, <I>very low quality of evidence</I>), length of intensive care unit stay (MD 0.54, 95% CI -2.27 to 3.34, seven trials, 934 participants, <I>very low quality of evidence</I>) or length of hospital stay (MD -3.33, 95% Cl -5.22 to -1.44, five trials, 693 participants, <I>very low quality of evidence</I>).</P>
<P>The quality of trial methodology was low. Due to high risk of bias in the included trials, results must be interpreted with caution.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-25 06:26:52 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Despite publication of a number of trials, the current evidence to recommend supplementation of critically ill patients with selenium or ebselen remains disputed. Trials are required which overcome the methodological inadequacies of the reviewed studies, particularly in relation to sample size, design and outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-22 16:51:57 +0100" MODIFIED_BY="Jane Cracknell">
<BACKGROUND MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<CONDITION MODIFIED="2015-07-25 10:38:46 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Critical illness is characterized by hyperinflammation, cellular immune dysfunction, oxidative stress and mitochondrial dysfunction. Oxidative stress reflects an imbalance between highly reactive oxygen molecules, known as free radicals, and the ability of the body to counteract their harmful effects through neutralization by antioxidants. Selenium is a trace mineral that is essential to this neutralization. Selenium-containing proteins include glutathione peroxidases and thioredoxin reductases (<LINK REF="REF-Angstwurm-2006" TYPE="REFERENCE">Angstwurm 2006</LINK>), which are antioxidant enzymes essential for the removal of damaging reactive oxygen species (ROS). ROS damage proteins, polysaccharides, nucleic acids and polyunsaturated fatty acids, which may lead to cell death (<LINK REF="REF-Geoghegan-2006" TYPE="REFERENCE">Geoghegan 2006</LINK>). Selenium deficiency impairs the immune response; and supplementation in replete people appears to enhance the immune response (<LINK REF="REF-Rayman-2012" TYPE="REFERENCE">Rayman 2012</LINK>). The iodothyronine deiodinase enzymes, which control the production of the hormone triiodothyronine from thyroxine, also require selenium.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium intake from plants (and thus animals) generally reflects the levels present in soils. There is particular concern that intake in people living in most parts of Europe is insufficient (<LINK REF="REF-Rayman-2012" TYPE="REFERENCE">Rayman 2012</LINK>); intakes are generally higher in people living in North America. Selenium status is further impaired in people with poor quality diets, such as alcoholics, and when dietary intake is reduced, for example during a chronic illness and gastrointestinal malfunction.</P>
<P>Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is an organic selenium-containing compound which appears to act as a mimic of glutathione peroxidase; it may thus also have anti-oxidant properties (<LINK REF="REF-Parnham-2000" TYPE="REFERENCE">Parnham 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-07-25 10:50:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Evidence suggests that excessive oxidative stress plays an important role in the development of complications of critical illness, such as the systemic inflammatory response which leads to acute respiratory distress syndrome (ARDS) and multiple organ failure (<LINK REF="REF-Bulger-2001" TYPE="REFERENCE">Bulger 2001</LINK>). Selenium appears to be pivotal in this role (<LINK REF="REF-Manzanares-2009" TYPE="REFERENCE">Manzanares 2009</LINK>). <LINK REF="REF-Berger-2007" TYPE="REFERENCE">Berger 2007</LINK> reported fewer infections after major burns compared with placebo when providing an antioxidant trace element supplement containing selenium, zinc and copper. <LINK REF="REF-Giladi-2011" TYPE="REFERENCE">Giladi 2011</LINK> similarly reported that antioxidant supplementation with vitamin C, vitamin E and selenium in people with severe trauma was associated with fewer infections and less organ dysfunction compared to placebo.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-07-25 06:26:52 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In the last two decades, several clinical trials have evaluated the role of antioxidant micronutrients either as a monotherapy or in combined therapy, as part of an antioxidant strategy for critically ill patients.</P>
<P>Several systematic reviews have reported reduced risk of mortality as a result of selenium supplementation (<LINK REF="REF-Heyland-2005" TYPE="REFERENCE">Heyland 2005</LINK>; <LINK REF="REF-Huang-2013" TYPE="REFERENCE">Huang 2013</LINK>; <LINK REF="REF-Landucci-2014" TYPE="REFERENCE">Landucci 2014</LINK>; <LINK REF="REF-Manzanares-2012" TYPE="REFERENCE">Manzanares 2012</LINK>).</P>
<P>The organic selenium-containing compound ebselen has also been investigated for its antioxidant properties in critical illness (<LINK REF="REF-Parnham-2000" TYPE="REFERENCE">Parnham 2000</LINK>).</P>
<P>We aimed to systematically review randomized controlled trials (RCTs) of either selenium or ebselen supplementation in adults with critical illness. More compelling evidence is needed on this subject and on its potential benefits.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-07-25 10:56:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>The primary objective was to examine the effect of nutrition supplemented with selenium or ebselen on mortality in critically ill patients.</P>
<P>The secondary objective was to examine the relationship between selenium or ebselen supplementation and number of infections, duration of mechanical ventilation, length of intensive care unit stay and length of hospital stay.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-20 07:11:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<CRIT_STUDIES MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We included RCTs irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted the trial investigators and authors for relevant data. We included unpublished trials only if trial data and methodological descriptions were provided either in written form or could be retrieved from the trial authors. We excluded cross-over trials. No cluster-RCTs were identified but we plan to include these, if found, in future updates.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>We included studies on adults with critical illness (including patients with burns, head injury, brain haemorrhage, cerebrovascular accident) and those undergoing elective major surgery.</P>
<P>Studies reporting mixed groups of participants (for example, combined data of critically ill and medical patients) were included only if data could be provided separately for patients with critical illness.</P>
<P>We excluded trials including neonates and participants aged under 18 years.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We included trials on nutritional interventions by the enteral or parenteral route, or both routes, supplemented with additional selenium versus nutritional care by the same route without additional selenium. We examined all types of selenium compounds including ebselen.</P>
<P>We undertook separate subgroup analyses of trials in which we calculated risk ratio (RR) for selenium/ebselen versus no selenium. If selenium was one of several components in an antioxidant supplement protocol, the trial was excluded based on our inability to assess the direct and isolated benefit of selenium.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<OL>
<LI>Overall mortality (longest follow-up, regardless of the period of follow-up).</LI>
<LI>Mortality by duration (studies reporting mortality for 28 and 90 days).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-12-01 11:02:58 +0000" MODIFIED_BY="Mikkel Allingstrup">
<OL>
<LI>Number of infectious complications (as defined in each of the included studies).</LI>
<LI>Adverse events.</LI>
<LI>Length of stay in an intensive care unit (ICU).</LI>
<LI>Number of days on a ventilator.</LI>
<LI>Length of hospital stay.</LI>
<LI>Quality of life after discharge (as defined in the included studies).</LI>
<LI>Economic outcomes.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-26 16:27:14 +0100" MODIFIED_BY="Mikkel Allingstrup">
<ELECTRONIC_SEARCHES MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this review update, we performed a search update up to 20 May 2014. Thus, we searched the Cochrane Central Register of Controlled Trials (the Cochrane Library 2014, Issue 5; see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We updated our search of MEDLINE (Ovid SP, to May 20, 2014, see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and EMBASE (Ovid SP, to May 20, 2014, see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). The search is now from inception until 21 May 2014</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-07-26 16:27:14 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We handsearched the reference lists of reviews (<LINK REF="REF-Huang-2013" TYPE="REFERENCE">Huang 2013</LINK>; <LINK REF="REF-Landucci-2014" TYPE="REFERENCE">Landucci 2014</LINK>; <LINK REF="REF-Manzanares-2012" TYPE="REFERENCE">Manzanares 2012</LINK>), randomized and non-randomized studies, and editorials for additional studies. We searched the <LINK REF="REF-ASPEN" TYPE="REFERENCE">ASPEN</LINK> and <LINK REF="REF-ESPEN" TYPE="REFERENCE">ESPEN</LINK> databases without finding references to selenium or ebselen. References were crosschecked with our search in MEDLINE. We contacted the main authors of included studies to ask for any missed, unreported or ongoing studies.</P>
<P>We searched for ongoing clinical trials and unpublished studies on the following Internet sites:</P>
<OL>
<LI>
<A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>
</LI>
<LI>
<A HREF="http://clinicaltrials.gov">http://clinicaltrials.gov</A>
</LI>
<LI>
<A HREF="http://www.centerwatch.com">http://www.centerwatch.com</A>
</LI>
</OL>
<P>No language restriction was applied to eligible reports. The latest search was performed 22 October 2014.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-20 07:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MA, AA) independently screened and classified all citations as potential primary studies, review articles or other. Also, the two review authors independently examined all potential primary studies and decided on their inclusion in the review. Data on methodology and outcomes from each trial were independently extracted and evaluated in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreements by consensus among the review authors.</P>
<STUDY_SELECTION MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We assessed the articles identified from the described searches and excluded obviously irrelevant reports. Two review authors (MA, AA) independently examined articles for eligibility and screened the titles and abstracts in order to identify studies for eligibility (see: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). This process was performed without blinding of authors, institution, journal of publication or results. We resolved any disagreements by consensus among the review authors. We provide a detailed description of the search and assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We independently extracted and collected the data without being blinded to the author, source institution or the publication source of trials. We resolved disagreements by discussion and approached all first authors of the included trials for additional information on risks of bias. For more detailed information please see the '<LINK TAG="CONTRIBUTIONS" TYPE="SECTION">Contributions of authors</LINK>' section.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>We evaluated the validity and design characteristics of each trial. Trials were evaluated for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat (ITT) analysis and completeness of follow-up). We assessed each trial quality factor separately and defined the trials as having low risk of bias only if they adequately fulfilled all of the below described criteria.</P>
<P>1. Random sequence generation</P>
<P>Assessment of randomization: sufficiency of the method in producing two comparable groups before intervention.</P>
<P>Grade: &#8217;low risk&#8217;: a truly random process (e.g. random computer number generator, coin tossing, throwing dice); &#8217;high risk&#8217;: any non-random process (e.g. date of birth, date of admission by hospital or clinic record number or by availability of the intervention); or &#8217;unclear risk&#8217;: insufficient information. </P>
<P>2. Allocation concealment</P>
<P>Allocation method prevented investigators or participants from foreseeing assignment.</P>
<P>Grade: &#8217;low risk&#8217;: central allocation or sealed opaque envelopes; &#8217;high risk&#8217;: using open allocation schedule or other unconcealed procedure; or &#8217;unclear risk&#8217;: insufficient information. </P>
<P>3. Blinding</P>
<P>Assessment of appropriate blinding of the team of investigators and participants: person responsible for participant care, participants and outcome assessors.</P>
<P>Grade: &#8217;low risk&#8217;: blinding considered adequate if participants and personnel were kept unaware of intervention allocations after inclusion of participants into the study, and if the method of blinding involved a placebo indistinguishable from the intervention, as mortality is an objective outcome; &#8217;high risk&#8217;: not double-blinded, categorized as an open label study, or without use of a placebo indistinguishable from the intervention; &#8217;unclear risk&#8217;: blinding not described. </P>
<P>4. Incomplete outcome data</P>
<P>Completeness of outcome data, including attritions and exclusions.</P>
<P>Grade: &#8217;low risk&#8217;: numbers and reasons for drop-outs and withdrawals in the intervention groups described, or no drop-outs or withdrawals was specified; &#8217;high risk&#8217;: no description of drop-outs and withdrawals provided; &#8217;unclear risk&#8217;: report gave the impression of no drop-outs or withdrawals, but this was not specifically stated. </P>
<P>5. Selective reporting</P>
<P>The possibility of selective outcome reporting.</P>
<P>Grade: &#8217;low risk&#8217;: reported outcomes prespecified in an available study protocol, or, if this is not available, published report includes all expected outcomes; &#8217;high risk&#8217;: not all prespecified outcomes reported, reported using non-prespecified subscales, reported incompletely or report fails to include a key outcome that would have been expected for such a study; &#8217;unclear risk&#8217;: insufficient information. </P>
<P>6. Funding bias</P>
<P>Assessment of any possible funding bias:</P>
<P>Grade: &#8217;low risk&#8217;: reported no funding, funding from universities or public institutions; &#8217;high risk&#8217;: funding from private investors, pharmaceutical companies or trial investigator employed by the pharmaceutical company; &#8217;unclear risk&#8217;: insufficient information. </P>
<P>7. Other bias </P>
<P>Assessment of any possible sources of bias not addressed in domains 1 to 6.</P>
<P>Grade: &#8217;low risk&#8217;: report appears to be free of such biases; &#8217;high risk&#8217;: at least one important bias is present that is related to study design, early stopping because of some data-dependent process, extreme baseline imbalance, academic bias, claimed fraudulence or other problems; or &#8217;unclear risk&#8217;: insufficient information, or evidence that an identified problem will introduce bias. </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We calculated RRs with 95% confidence intervals (CIs) for dichotomous data (binary outcomes). These included:</P>
<P>Primary outcomes:</P>
<OL>
<LI>Mortality by duration and overall mortality.</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Number of infectious complications.</LI>
<LI>Adverse events.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We used the mean difference (MD) or RR if data were continuous and measured in the same way between trials. These included:</P>
<OL>
<LI>Length of stay in an ICU.</LI>
<LI>Number of days on a ventilator.</LI>
<LI>Length of hospital stay.</LI>
</OL>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We excluded cross-over trials from our meta-analyses because of the potential risk of "carry-over" of treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple intervention groups</HEADING>
<P>In studies designed with multiple intervention groups we combined groups to create a single pair wise comparison in accordance with <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>. In trials with two or more groups receiving different doses, we combined data for the primary and secondary outcomes.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We contacted the authors of trials with missing data in order to retrieve the relevant information. For all included studies we noted levels of attrition and any exclusion of participants. In case of missing data, we chose 'complete-case analysis' for our primary outcomes, which excludes from the analysis all participants with the outcome missing. Selective outcome reporting occurs when non-significant results are selectively withheld from publication (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>), and is defined as the selection, on the basis of the results, of a subset of the original variables recorded for inclusion in publication of trials (<LINK REF="REF-Hutton-2000" TYPE="REFERENCE">Hutton 2000</LINK>). The most important types of selective outcome reporting are: selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data; and selective under-reporting of data (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We explored heterogeneity using the I² statistic and Chi² test. An I² statistic above 50% represents substantial heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). In case of an I² statistic value &gt; 0 (mortality outcome), we tried to determine the cause of heterogeneity by performing relevant subgroup analyses. We used the Chi² test to provide an indication of heterogeneity between studies, with P &#8804; 0.1 considered significant.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-12-20 13:00:09 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Funding bias is related to the possible publication delay or discouragement of undesired results in trials sponsored by the industry (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). To explore the role of funding, we planned to conduct a sensitivity analysis based on our primary endpoint.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-10-20 07:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>Using <LINK REF="REF-RevMan-5.3" TYPE="REFERENCE">RevMan 5.3</LINK>, we calculated RR with 95% CIs for dichotomous variables and MD with 95% CIs for continuous outcomes. We used the Chi² test to provide an indication of heterogeneity between studies, with P &lt; 0.1 considered significant. The degree of heterogeneity observed in the results was quantified using the I² statistic, which can be interpreted as the proportion of the total variation observed between the studies that is attributable to differences between studies rather than sampling error (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). An I² statistic value &gt; 75% is considered very heterogeneous. We used both a random-effects model and a fixed-effect model. If the I² statistic value was 0 we only reported the results from the fixed-effect model; and in the case of the I² statistic value being &gt; 0 we reported only the results from the random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>Trial sequential analysis (TSA) is a methodology that combines an information size calculation for meta-analysis with a threshold of statistical significance. TSA is a tool for quantifying the statistical reliability of data in a cumulative meta-analysis, adjusting significance levels for sparse data and repetitive testing on accumulating data. We conducted TSA (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Pogue-1997" TYPE="REFERENCE">Pogue 1997</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>) at least on the primary outcomes and on the secondary outcomes if the accrued information size was an acceptable fraction of the estimated required information size to allow meaningful analyses (&gt; 20). If the actual accrued information size was too low, we provided the required information size given the actual diversity in case of low risk of bias (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>) or adjusted with a possible diversity of 25% in case of high risk of bias and absence of actual diversity.</P>
<P>Meta-analysis may result in type I errors due to random errors arising from sparse data or repeated significance testing when updating the meta-analysis with new trials (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). Bias (systematic error) from trials with low methodological quality, outcome measure bias, publication bias, early stopping for benefit and small trial bias may also result in spurious P values (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).<BR/>
<BR/>In a single trial, interim analysis increases the risk of type I errors. To avoid these, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value, i.e. the cumulative Z-curve crosses the monitoring boundaries (<LINK REF="REF-Lan-1983" TYPE="REFERENCE">Lan 1983</LINK>). Sequential monitoring boundaries can also be applied to meta-analysis, and are called trial sequential monitoring boundaries. In TSA, the addition of each trial in a cumulative meta-analysis is regarded as an interim meta-analysis and helps to clarify whether additional trials are needed.</P>
<P>The idea in TSA is that if the cumulative Z-curve crosses the boundary, a sufficient level of evidence is reached and no further trials may be needed (firm evidence). If the Z-curve does not cross the boundary, then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries the required information size is needed and is calculated as the least number of participants needed in a well-powered single trial (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Pogue-1997" TYPE="REFERENCE">Pogue 1997</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-Trial-Sequential-Analysis-_x0028_TSA_x0029_" TYPE="REFERENCE">Trial Sequential Analysis (TSA)</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). We aimed to apply TSA as it prevents an increase in the risk of type I error with sparse data or multiple updating in a cumulative meta-analysis. Hence, TSA provides us with important information in order to estimate the level of evidence of the experimental intervention, the need for additional trials and their sample size.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-07-25 06:26:53 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We conducted the following subgroup analyses:</P>
<OL>
<LI>Mortality by duration. We planned to use 28, 90 days and the longest follow-up period. If data were provided in 30 days we included them in the same analysis as 28 days.</LI>
<LI>Mortality among patients admitted in a general ICU.</LI>
<LI>Mortality among patients admitted under the diagnosis of acute pancreatitis.</LI>
<LI>Number of infected participants.</LI>
<LI>Number of participants with adverse event.</LI>
<LI>Length of stay in the ICU.</LI>
<LI>Number of days on a ventilator.</LI>
<LI>Length of hospital stay.</LI>
</OL>
<P>We considered P values &lt; 0.05 as indicating significant interaction between the subgroup category.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>We decided to carry out a sensitivity analysis on the results by applying fixed-effect and random-effects models to assess the impact of heterogeneity on our results.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We used the principles of the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach to provide an overall assessment of the evidence relating to the following outcomes: Overall mortality (regardless of the follow-up period), ICU length of stay (selenium), Days on ventilator (selenium), Length of hospital stay (selenium) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-22 16:51:47 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY_DESCRIPTION MODIFIED="2016-04-22 16:51:47 +0100" MODIFIED_BY="Jane Cracknell">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> sections.</P>
<SEARCH_RESULTS MODIFIED="2015-07-25 14:49:24 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this updated review, 11 trials was identified via the search strategy, 6 were included, 5 were excluded, two were classified as ongoing and two are awaiting assessment. We have listed the reasons for excluding the 5 studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. Three included studies and three excluded studies were published in German only, and one included trial was in Spanish. Translations to English were performed for these studies. Some trials had multiple full text publications (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>). A total of 2084 patients were included in this review update.</P>
<P>Of the six new included studies, we found one by handsearching (<LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>) and five using our search string (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>). We sought further details and obtained them for four studies (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>). The flow chart for this updated review is given in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-04-22 16:51:47 +0100" MODIFIED_BY="Jane Cracknell">
<P>The included trials were all published between 1997 and 2013 except for one trial which was published in 1991 (<LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>). Three trials of ebselen were Japanese multicentre trials (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>). One trial of selenium was a multicentre trial in Germany (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>), one was a multicentre trial in the UK (<LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>) and one was a multicentre trial in France (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>). The remaining Selenium trials were single centre trials in the Czech Republic, Germany, Switzerland, the UK and Uruguay (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>). One trial did not state the location (<LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>).</P>
<P>The 16 included studies involved a total of 2084 participants. We have provided the details of the included studies in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' section. Eleven trials recruited more male than female participants (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>). One trial recruited only men (<LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>), one did not report the sex of the participants (<LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>) and three studies had more women than men (<LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>). Where reported, the mean age of participants was greater than 50 years. Two trials excluded participants older than 75 and 71 years, respectively (<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>).</P>
<P>Trials of selenium recruited participants with the following conditions: sepsis or systemic inflammatory response syndrome (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>), severe multiple injury (<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>), more serious cases of acute pancreatitis (<LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>) and gastrointestinal failure requiring parenteral nutrition (56% with sepsis; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>). The three trials of ebselen were conducted in participants with acute neurological conditions: acute middle cerebral artery occlusion (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>), aneurysmal subarachnoid haemorrhage (<LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>) and acute ischaemic stroke (<LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>).</P>
<P>It is unclear whether ebselen and selenium have similar mechanisms of action and thus, we chose not to consider them as identical interventions. For the ebselen trials, no details were provided concerning the need for ventilation or the level of critical illness care required.</P>
<P>The three neurological trials of ebselen (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>) all used an enteral dose of 300 mg daily for 14 days that was compared to a matching placebo. The trials of selenium used intravenous selenium, usually given as a sodium selenite, as a continuous infusion over 24 hours, with doses of selenium ranging from 155 mcg to 4000 mcg (often decreasing the dose as time went on). Four studies gave loading bolus doses on the first day (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>) and a fifth (<LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>) gave daily boluses. Only <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK> had no comparison infusion. No trial examined the impact of selenium or ebselen supplementation for more than 28 days.</P>
<P>
<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK> included three trial groups: selenium only, selenium combined with alpha-tocopherol and zinc, and placebo control. We have presented only the comparison between selenium and placebo. The <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK> trial included four study groups: glutamine only, selenium only, selenium combined with glutamine, and a placebo group. We pooled data for selenium only and selenium combined with glutamine as the treatment group, and glutamine only and placebo as the control group.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We excluded 16 studies (<LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Berger-2004a" TYPE="STUDY">Berger 2004a</LINK>; <LINK REF="STD-Berger-2004b" TYPE="STUDY">Berger 2004b</LINK>; <LINK REF="STD-Berger-2005a" TYPE="STUDY">Berger 2005a</LINK>; <LINK REF="STD-Berger-2005b" TYPE="STUDY">Berger 2005b</LINK>; <LINK REF="STD-Berger-2008" TYPE="STUDY">Berger 2008</LINK>; <LINK REF="STD-B_x00f6_rner-1997" TYPE="STUDY">Börner 1997</LINK>; <LINK REF="STD-Collier-2008" TYPE="STUDY">Collier 2008</LINK>; <LINK REF="STD-Kiessling-2006" TYPE="STUDY">Kiessling 2006</LINK>; <LINK REF="STD-Porter-1999" TYPE="STUDY">Porter 1999</LINK>; <LINK REF="STD-REDOXS-2011" TYPE="STUDY">REDOXS 2011</LINK>; <LINK REF="STD-Stoppe-2010" TYPE="STUDY">Stoppe 2010</LINK>; <LINK REF="STD-Thiele-1997" TYPE="STUDY">Thiele 1997</LINK>; <LINK REF="STD-Uden-1990" TYPE="STUDY">Uden 1990</LINK>; <LINK REF="STD-Watters-2002" TYPE="STUDY">Watters 2002</LINK>; <LINK REF="STD-Wollschl_x00e4_ger-1997" TYPE="STUDY">Wollschläger 1997</LINK>) for the reasons detailed in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' section.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Two studies are ongoing (<LINK REF="STD-Geoghegan-2009" TYPE="STUDY">Geoghegan 2009</LINK>; <LINK REF="STD-Yamaguchi-2003" TYPE="STUDY">Yamaguchi 2003</LINK>; see the '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting classification</HEADING>
<P>Two studies are awaiting classification (<LINK REF="STD-SEREAL-2012" TYPE="STUDY">SEREAL 2012</LINK>; <LINK REF="STD-SISPCT" TYPE="STUDY">SISPCT</LINK>; see the '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' section.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-27 12:43:40 +0100" MODIFIED_BY="Jane Cracknell">
<P>The risk of bias of the included studies was high. The trials often failed to report trial methodology in sufficient detail. One trial had improved methodology after further details were obtained from one trial author (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>). See <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>
</P>
<P>All but one of the included studies were RCTs; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK> was a quasi-RCT. <B>
<BR/>
</B>
<BR/>In eight trials groups were clearly comparable at baseline (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>). Four trials did not clearly report following up all participants to the end of the trial (<LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>). All trials clearly reported the treatments given for the trial but no trial clearly described the co-interventions as being equally provided to all groups. Six trials gave objectively described definitions of trial outcomes (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>).</P>
<ALLOCATION MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Concealment of allocation was confirmed in only three trials (<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>). The other trials did not clearly report the method of concealment of allocation. Although not always explicitly stated, ITT analysis was undertaken in seven of the 16 trials (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>). The risk of selection bias is high.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-21 14:36:56 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Ten trials were reported to be blinded or double blinded (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>, <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>). For the outcomes assessed in this review, it was often unclear to whom the blinding referred. Only <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK> and <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK> recruited consecutive eligible patients. Due to the poorly described level of blinding in most trials, the risk of bias remains unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>One trial, <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>, had a follow-up period of 10 days. The average (median) length of mechanical ventilation in the control group was 13 days compared to nine days in the intervention group. The median length of stay in hospital was 17 days for the control group and 12 days for the intervention group. It remains unclear how long the patients indeed were followed-up. Most trials poorly described or failed to describe the follow-up period (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>). The risk of attrition bias is thus high.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Only two trials had published a protocol or registered the trial in an available database (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>). Thus, for most trials we are unable to assess the degree of reporting bias. The overall risk of bias is high for selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="4">Funding bias</HEADING>
<P>Four studies provided a conflict of interest statement (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>). Five trials reported receiving pharmaceutical company funding (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>), and in one trial a study was acknowledged for providing the study drug (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-27 12:53:10 +0100" MODIFIED_BY="Jane Cracknell">
<P>The outcomes reported in the included studies are listed in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. Where available, we have presented mortality results using denominators based on the numbers of participants at randomization. Generally, we have presented the results for other outcomes using denominators based on the numbers of participants available at follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>All 16 included studies provided mortality data, 13 trials used selenium as intravenous sodium selenite (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>) and three trials used ebselen (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>).</P>
<P>In trials of selenium, overall mortality was reduced in the intervention group (RR 0.82, 95% Cl 0.72 to 0.93, I² statistic = 0%, fixed-effect model) while for ebselen the RR in favour of intervention among trials was 0.83 (95% Cl 0.52 to 1.34, I² statistic = 0%, fixed-effect model). Combined data for mortality showed a RR of 0.82 (95% Cl 0.72 to 0.93; I² statistic = 0%, test for subgroup differences: I² statistic = 0%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Twenty-eight days mortality among selenium studies yielded a RR of 0.84 (Cl 95% 0.69 to 1.02, I² statistic = 21%, random-effects model) while at 90 days RR was 0.96 (95% CI 0.78 to 1.18, I² statistic = 0% random-effects model) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Inclusion of the data from the three trials of ebselen showed no statistically significant difference in mortality (RR 0.83, 95% CI 0.52 to 1.34; I² statistic = 0%). Only <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK> reported mortality at 30 days (RR 1.78, 95% CI 0.53 to 5.95) while <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK> and <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK> reported mortality data at three months follow-up (RR 0.72, 95% CI 0.42 to 1.22) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Mortality in trials of selenium in intensive care patients (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>) compared with trials in patients with acute pancreatitis (<LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>) yielded a RR of 0.88 (95% CI 0.77 to 1.01, I² statistic = 0%, random-effects model). In patients with acute pancreatitis the RR was 0.40 (95% CI 0.01 to 12.30, I² statistic = 81% random-effects model) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Number of infectious complications</HEADING>
<P>Six trials of intravenous sodium selenite provided data on this outcome (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>).</P>
<P>
<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK> provided data for participants developing infections based on the number of participants requiring antibiotics. <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK> reported no significant difference in the incidence of new infections (for example the development of hospital acquired pneumonia, as well as the incidence of acute respiratory distress syndrome). <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK> reported participants with at least one episode of nosocomial pneumonia and one participant on selenium developing a superinfection. Similarly, <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK> reported participants with ventilator-associated pneumonia. <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK> provided data on patients developing sepsis or peritonitis. <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK> reported new infections at 14 days post-randomization (both clinically suspected infections (used in our meta-analysis)) and infections confirmed and based on Centers for Disease Control and Prevention criteria (reported odds ratio 0.75, 95% CI 0.52 to 1.08, P = 0.12). Based on data from these six trials, there was no statistically significant difference (RR 0.96, 95% CI 0.75 to 1.23, I² statistic = 16%, random-effects model; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK> reported an infection rate instead of number of infections; consequently the data could not be included but no significant difference between groups was found.</P>
<P>All three trials of ebselen (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>) provided data for participants developing infections (pyrexia, respiratory infections or meningitis) with no statistically significant difference (RR 0.60, 95% CI 0.36 to 1.02, I² statistic = 33%, random-effects model; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Trial investigators reported a wide variety of individual adverse events, including: organ failure, shock, requirement for inotropic support, requirement for fluids or transfusion, gastrointestinal bleeding, cerebral infarction and haemorrhage, nausea and vomiting, acute myocardial infarction, pulmonary embolism, enterocolitis, pancreatitis and skin rash. <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK> reported that renal failure requiring continuous veno-venous haemodialysis was required for three of the 21 participants receiving intravenous sodium selenite and nine of the 21 participants in the control group. <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK> reported that the need for haemodialysis or vasopressor therapy was identical in the two groups and that adverse events occurred in 110/122 of the intravenous sodium selenite group and 119/124 of the placebo group. Three trials reported numbers of participants developing any serious adverse event (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>). <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK> reported that five of the 18 selenium supplemented participants required renal replacement compared with seven of the 22 controls. The RR for an adverse event from these six trials was 1.03 (95% CI 0.85 to 1.24, I² statistic = 41%; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>In the three trials of ebselen, the overall incidence of adverse events in the ebselen and placebo groups were reported as 7.3% and 3.3%, respectively (<LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>); 10% and 14%, respectively (<LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>); and as not significantly different (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>). Combining the results for <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK> and <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK> (no available data for <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>) yielded a RR of 1.16 (95% CI 0.40 to 3.36, I² statistic = 68%; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of stay in ICU</HEADING>
<P>Seven trials of intravenous sodium selenite provided data on the length of stay in intensive care (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Three trials provided data directly suitable for meta-analysis (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>). Four trials (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>) provided data which had to be processed. The overall MD was 0.54 (95% CI -2.27 to 3.34, I² statistic = 72%, random-effects model; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2)</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of days on a ventilator</HEADING>
<P>Five trials of intravenous sodium selenite provided data for the number of days on a ventilator (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Four trials provided data suitable for meta-analysis (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). One trial, <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>, reported the incidence and hours of mechanical ventilation as not significantly different between groups (mean of 13 days with selenium for 84 participants and 11 days with placebo for 95 participants), but stated no range of days. The overall MD was -0.86 (95% CI -4.39 to 2.67, I² statistic = 89%, random-effects model; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>Five trials, all of intravenous sodium selenite, provided data on the length of hospital stay (<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The overall MD was -3.33 (95% CI -5.22 to -1.44, I² statistic = 42%, random-effects model; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life after discharge</HEADING>
<P>Trials of ebselen (<LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>; <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK>; <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>) reported no statistically significant difference in Glasgow Outcome Scales (<LINK REF="REF-Jennett-1975" TYPE="REFERENCE">Jennett 1975</LINK>) at final follow-up. However, <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK> reported that the Modified Barthel Index Score (<LINK REF="REF-Shah-1989" TYPE="REFERENCE">Shah 1989</LINK>), an assessment of functional status, was significantly improved by ebselen at a final follow-up time of three months.</P>
<P>Only one trial, <LINK REF="STD-Ogawa-1999" TYPE="STUDY">Ogawa 1999</LINK>, stated the results in values. The other two trials, <LINK REF="STD-Saito-1998" TYPE="STUDY">Saito 1998</LINK> and <LINK REF="STD-Yamaguchi-1998" TYPE="STUDY">Yamaguchi 1998</LINK>, showed only a graphical representation. Consequently, we were unable to make an analysis for this subgroup.</P>
<P>No trials of selenium have provided quality of life data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Economic outcomes</HEADING>
<P>No trials provided details of costs or economic outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other findings</HEADING>
<P>Six trials found significantly increased activity of the antioxidant selenoenzyme glutathione peroxidase, demonstrating the potential for intravenous selenium to improve antioxidant capacity in participants (<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>). The measurement of selenium levels in the blood may be an unreliable marker of selenium status because levels fall with an acute phase response provoked by injury or infection (<LINK REF="REF-Sattar-1997" TYPE="REFERENCE">Sattar 1997</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials sequential analysis (TSA):</HEADING>
<P>Since TSA was not part of the previous version of this review, <LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>, we used the calculated relative risk and event rates of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> to calculate the required information size. In our TSA of the impact of selenium supplementation on mortality among critically ill patients using a control event proportion of 32% found in the included trials, with a type 1 error of 5% and a 18% relative risk reduction (80% power), the trial sequential monitoring boundary for benefit is not crossed by the z-curve (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). However, these lines are very close to crossing each other. This may suggest a probability of lack of random error for the conclusion of an effect of 18% relative risk reduction even though the required information size (N = 2605) has not yet been reached. Nevertheless, one must exert caution when interpreting the results of our TSA on mortality since all included studies are at high risk of bias and the intervention effect is likely to have been overestimated in the traditional meta-analysis. This will inevitably influence the TSA result. As a general rule TSA is unable to adjust for risk of bias and is ideally designed for studies with low risk of bias. Thus, we anticipate a higher degree of heterogeneity and diversity, and consequently a different TSA output once the results of the ongoing large RCTs are published.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-22 16:51:57 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY_OF_RESULTS MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this review update we found no clear evidence that selenium supplementation reduces mortality in critically ill adults despite a statistically significant finding. This is mainly due to the high risk of bias, most likely overestimating the overall intervention effect. Even though we are unable to rule out a beneficial effect, the evidence remains dubious as a result of the poor methodological quality of the trials. For instance, only three trials clearly reported concealment of allocation (<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>). Few trials reported on outcomes other than mortality or clearly defined the reported outcomes. Periods of follow-up were often short and did not allow for the prolonged recovery from critical illness. There was insufficient data to examine the effect of methodological superiority or dose of selenium on the outcomes.</P>
<P>Selenium supplementation in the general ICU population with severe sepsis or septic shock has been investigated by <LINK REF="STD-SISPCT" TYPE="STUDY">SISPCT</LINK>, which with a sample size of 1180 and rigorous methodology may help clarifying a potential benefit or harm of selenium. The lead author of <LINK REF="STD-SISPCT" TYPE="STUDY">SISPCT</LINK> expects to publish the results within the next year. Additionally, based on data from current published trials it remains at best uncertain as to whether loading bolus or continuous doses are preferred (<LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>).</P>
<P>There was no clear evidence of benefit from the use of ebselen in patients with stroke or subarachnoid haemorrhage. The results of one large trial, <LINK REF="STD-Yamaguchi-2003" TYPE="STUDY">Yamaguchi 2003</LINK>, are still awaited.</P>
<P>Furthermore, we found no evidence to suggest that these interventions are harmful.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We are confident that we identified all available studies from our search strategy. Several authors have been contacted but have not identified any additional trials for inclusion.</P>
<P>In contrast to <LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>, in this update we revised the primary endpoints, adding overall mortality regardless of the period of follow-up, and carried out TSA in order to reduce the risk of random error. Yet, the review conclusions remain the same.</P>
<P>The applicability of our results only refers to critically ill adult patients and as such there is insufficient evidence to support the routine use of this intervention.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-22 16:51:57 +0100" MODIFIED_BY="Jane Cracknell">
<P>The RCT is considered the most rigorous method for determining whether a cause-effect relationship exists between an intervention and outcome. The strength of the RCT lies in the process of randomization.</P>
<P>No trials were reported as at overall low-risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Fifteen of the 16 included trials were at high risk of bias regarding random sequence generation (selection bias). Only one trial has published the protocol (<LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>) and only two trials had been registered in a database (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>), which is why we deemed 14 of the 16 included trials at high risk of reporting bias. All trials of ebselen were at high risk of funding bias. Thus, due to the overall high risk of bias in these included trials, the results should be interpreted with caution.</P>
<P>Application of the GRADE approach enables us to incorporate risk of bias, directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias. Based on the above mentioned criteria, the quality of evidence in this review was very low and there was a high risk of bias</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this update we remained loyal to the original protocol, <LINK REF="REF-Avenell-2002" TYPE="REFERENCE">Avenell 2002</LINK>, with only minor changes in order to avoid bias. Two review authors (MA, AA) independently performed data extraction and 'Risk of bias' assessment. We consulted the Managing Editor and Trials Search Coordinator of the Cochrane Anaesthesia, Critical and Emergency Care Group throughout the entire process of the review update.</P>
<P>Despite our prior knowledge to the conclusions of other recently published systematic reviews (<LINK REF="REF-Huang-2013" TYPE="REFERENCE">Huang 2013</LINK>; <LINK REF="REF-Landucci-2014" TYPE="REFERENCE">Landucci 2014</LINK>; <LINK REF="REF-Manzanares-2012" TYPE="REFERENCE">Manzanares 2012</LINK>), we have adhered to Cochrane methodology and applied additional statistical methods, such as TSA, to strengthen our conclusions and reduce the risk of random error.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-07-25 06:26:54 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>The overall conclusions of this Cochrane review do not agree with the statements and findings of the most recently published systematic reviews and meta-analysis (<LINK REF="REF-Huang-2013" TYPE="REFERENCE">Huang 2013</LINK>; <LINK REF="REF-Landucci-2014" TYPE="REFERENCE">Landucci 2014</LINK>; <LINK REF="REF-Manzanares-2012" TYPE="REFERENCE">Manzanares 2012</LINK>). All three meta-analyses reported a significantly decreased mortality in the selenium group. However, two papers did not address the quality of studies included (<LINK REF="REF-Huang-2013" TYPE="REFERENCE">Huang 2013</LINK>; <LINK REF="REF-Manzanares-2012" TYPE="REFERENCE">Manzanares 2012</LINK>). <LINK REF="REF-Landucci-2014" TYPE="REFERENCE">Landucci 2014</LINK> reported the quality of evidence of the meta-analysis as low due to unclear quality of randomization in many studies. These papers did not adhere to PRISMA guidelines.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<IMPLICATIONS_PRACTICE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>Despite a statistically significant finding on longest follow-up mortality (RR 0.82, 95% CI 0.72 to 0.93), one must be cautious when interpreting the strength of the evidence for the routine use of selenium or ebselen supplementation in critically ill patients. Serious methodological shortcomings of the included studies are likely to have influenced the overall intervention effect (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Additionally, we failed to show a reduced time on mechanical ventilation, length of stay in ICU or length of stay in hospital. Our review did not indicate any harmful effect of the intervention among critically ill patients.</P>
<P>The GRADE approach only reaffirmed our interpretation of the level of evidence and we are confident that at this stage the quality of evidence is very low and risk of bias very high.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-07-25 13:55:08 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We await the publication of the large multicentre RCT, <LINK REF="STD-SISPCT" TYPE="STUDY">SISPCT</LINK>, as it will provide important information essential to calculate the required information size in order to reject or accept a beneficial effect of selenium supplementation. Based on our current TSA, the required information size of 2605 patients is not far from the 2084 patients included in this paper. However, large, well-designed, adequately powered trials of selenium supplementation, at low risk of bias and conforming to the CONSORT statement (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>), will most likely increase the required information size. Future research should examine functional status, patient-perceived quality of life and include economic evaluation. Independent observers should assess outcomes and the period of follow-up should extended and preferably exceed current arbitrary defined short limits (i.e. 28 days up to six months).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<P>We thank the review authors of the first edition of this review, Alison Avenell, David Noble, John Barr and Tom Engelhardt, for their hard work (<LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>).</P>
<P>Furthermore we thank Mette Berger, Helena Brodska, Xavier Forceville, Roland Gärtner, Frank Bloos, Arndt Kiessling, William Manzanares and Tomoko Motohashifor for providing further information about their trials. We are grateful to Matilde Jo Allingstrup, Tim Søvæld Nielsen, Jesper Røjskjær and Anders Perner for their help and editorial advice during this review update. We acknowledge Dr Karen Hovhannisyan (Trials Search Co-ordinator, Cochrane Anaesthesia, Critical and Emergency Care Group (ACE) ) for his assistance in providing our different search strategies. We thank Jane Cracknell (Managing Editor, ACE) for her valuable assistance during the entire process.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Mikkel Allingstrup declares no conflicts of interest.</P>
<P>Arash Afshari declares no conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<SUBSECTION>
<HEADING LEVEL="2">Updated review</HEADING>
<P>Mikkel Allingstrup (MA), Arash Afshari (AA).</P>
<P>MA and AA searched the literature, performed quality assessment and extraction of data from trials, and wrote the review update.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Original published review and first update</HEADING>
<P>All four authors (Alison Avenell, David W Noble, John Barr, Thomas Engelhardt) were involved in protocol development, searched the literature, performed quality assessment and data abstraction of trials, and wrote the review (<LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>).</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>In this review update we have revised the first primary endpoint to overall mortality, which is the longest time of follow-up. Mortality by duration (28 and 90 days) is preserved as our second primary endpoint. We performed a TSA and included it in this review update.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>2015 update: we updated the methods, included full 'Risk of bias' tables and 'Summary of findings' tables. We used TSA.</P>
<P>This review was also updated in 2007 (<LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>). At that time Cochrane updates did not earn a new citation unless they had new authors or a change to conclusions. The 2007 version of this review included three new trials; two of these were previously classified as ongoing trials (<LINK REF="REF-Angstwurm-2006" TYPE="REFERENCE">Angstwurm 2006</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>). The conclusions of the 2007 review were unchanged. Therefore the 2007 update did not earn a new citation</P>
<P>We thank Mathew Zacharias, Nathan Pace, Naji Abumrad, Daren Heyland, Saúl Rugeles, Ann Moller, Iveta Simera, Kathie Godfrey and Amy Godfrey Arkle for their help and editorial advice during the preparation of the original review (<LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-20 07:20:18 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Angstwurm-1999" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Angstwurm 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm MWA, Schopohl J, Gaertner R</AU>
<TI>Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients</TI>
<SO>European Journal of Endocrinology</SO>
<YR>2004</YR>
<VL>151</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS MODIFIED="2015-07-25 13:31:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 13:31:25 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="MEDLINE" VALUE="PMID: 15248821"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm MWA, Schottdorf J, Schopohl J, Gaertner R</AU>
<TI>Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1807-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10507602"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 21:48:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gärtner R, Angstwurm MWA, Schopohl J</AU>
<TI>Selenium replacement in patients with SIRS improves clinical outcome</TI>
<SO>Clinical Nutrition</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gärtner R, Angstwurm MWA, Schottdorf J</AU>
<TI>Selenium administration in sepsis patients</TI>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>12-4</PG>
<IDENTIFIERS MODIFIED="2015-07-25 13:29:21 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 13:29:21 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="9417486"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angstwurm-2007" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Angstwurm 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm MW, Englemann L, Zimmermann T, Lehmann C, Spes CH, Abel P, et al</AU>
<TI>Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>1</NO>
<PG>118-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm MWA, Gaertner R</AU>
<TI>Selenium substitution in severe sepsis as useful additive? Preliminary results of the SIC study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forceville X</AU>
<TI>The need for precise dose information of sodium selenite in the SIC study and rectification of GPx-3 plasma concentration</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>2</NO>
<PG>656-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forceville X</AU>
<TI>The need for precise dose information of sodium selenite in the SIC study and rectification of GPx-3 plasmaconcentration. Erratum</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>7</NO>
<PG>2224</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-25 14:57:55 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gaertner R</AU>
<TI>Sodium selenite as an adjunctive therapy for sepsis - clinical data from a multi-centre intervention study (SIC Study)</TI>
<SO>DIVI Congress, Hamburg, Symposium 'Adjunctive therapy in sepsis: what has been confirmed?'</SO>
<YR>4 December 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schomburg L</AU>
<TI>Selenium in Intensive Care (SIC) study: the XX files are still unresolved</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>3</NO>
<PG>995-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2001" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Berger 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-07-23 22:05:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Baines M, Chioléro RL, Wardle CA, Cayeux C, Shenkin A</AU>
<TI>Influence of early trace element and vitamin E supplements on antioxidant status after major trauma: a controlled trial</TI>
<SO>Nutrition Research</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>41-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Reymond MJ, Shenkin A, Rey F, Wardle C, Cayeux C, et al</AU>
<TI>Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>1</NO>
<PG>91-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11280679"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forceville-2007" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Forceville 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>Forceville X, Bellissant E</AU>
<TI>Selenium, as sodium selenite, in the treatment of septic shock</TI>
<SO>http://clinicaltrials.gov/show/NCT00207844</SO>
<YR>(accessed 8 August 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Forceville X, Lavoille B, Annane D, Vitoux D, Bleichner G, Korach JM, et al</AU>
<TI>Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study</TI>
<SO>Critical Care</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>4</NO>
<PG>R73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janka-2013" MODIFIED="2015-07-25 14:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Janka 2013" YEAR="2012">
<REFERENCE MODIFIED="2015-07-25 14:57:46 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Janka V, Ladislav K, Jozef F, Ladislav V</AU>
<TI>Restoration of antioxidant enzymes in the therapeutic use of selenium in septic patients&#8233;</TI>
<SO>Wiener klinische Wochenschrift</SO>
<YR>2013</YR>
<VL>125</VL>
<NO>11-2</NO>
<PG>316-25</PG>
<IDENTIFIERS MODIFIED="2014-11-03 11:11:15 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-11-03 11:11:13 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1007/s00508-013-0371-x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-03 11:10:19 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuklinski-1991" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Kuklinski 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuklinski B, Buchner M, Schweder R, Nagel R</AU>
<TI>Acute pancreatitis - a "free radical disease". Decrease of lethality by sodium selenite (Na2SeO3) therapy</TI>
<TO>Akute pankreatitis - eine "free radical disease". Letalitatssenkung durch natriumselenit (Na2SeO3)-therapie</TO>
<SO>Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>5</NO>
<PG>145-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1648849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindner-2004" NAME="Lindner 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindner D, Lindner J, Baumann G, Dawczynski H, Bauch K</AU>
<TI>Investigation of antioxidant therapy with sodium selenite in acute pancreatitis. A prospective randomized blind trial</TI>
<TO>Untersuchung zur antioxidativen therapie mit natriumselenit bei akuter pankreatitis. Eine prospektive, randomisierte blindstudie</TO>
<SO>Medizinische Klinik</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>12</NO>
<PG>708-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15599680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manzanares-2011" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Manzanares 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manzanares W, Biestro A, Torre MH, Galusso F, Fachin G, Hardy G</AU>
<TI>High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1120-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishra-2007" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Mishra 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-23 22:13:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishra V, Baines M, Perry S, McLaughlin J, Carson J, Wenstone R, et al</AU>
<TI>Selenium supplementation and outcome in septic ICU patients</TI>
<SO>Clinica Chimica Acta</SO>
<YR>2005</YR>
<VL>355</VL>
<NO>Suppl 1</NO>
<PG>S45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mishra V, Baines M, Perry SE, McLaughlin PJ, Carson J, Wenstone R, et al</AU>
<TI>Effect of selenium supplementation on biochemical markers and outcome in critically ill patients</TI>
<SO>Clinical Nutrition</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>41-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:14:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishra V, Perry S, Baines M, McLaughlin J, Carson J, Wenstone R, et al</AU>
<TI>Selenium replacement, HLA-DR expression and outcome in septic ICU patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montoya-2009" MODIFIED="2015-07-23 22:16:15 +0100" MODIFIED_BY="[Empty name]" NAME="Montoya 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-23 22:16:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montoya CG, Luna AH, Silva JAV, Guzmán CO, Sánchez JA, Granillo JF</AU>
<TI>High doses of selenium in severe sepsis</TI>
<TO>Efecto antiinflamatorio del selenio en pacientes se&#769;pticos</TO>
<SO>Revista de la Asociación Mexicana de Medicina Crítica y Terapia Intensiva</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>199-205</PG>
<IDENTIFIERS MODIFIED="2014-12-12 15:08:54 +0000" MODIFIED_BY="Jane Cracknell"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-03 11:11:54 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogawa-1999" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Ogawa 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, et al for the Ebselen Study Group</AU>
<TI>Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>2</NO>
<PG>112-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9973655"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-1998" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Saito 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-07-23 22:16:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asano T, Takakura K, Sano K</AU>
<TI>Comparative analysis of the clinical effects of water-soluble (AVS) and -insoluble (ebselen) antioxidants on the delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 1</NO>
<PG>188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:17:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito I, Abe H, Yoshimoto T, Asano T, Takakura K, Ohta T, et al</AU>
<TI>Multicentre randomised clinical trial of ebselen with aneurysmal subarachnoid hemorrhage</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>162</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, et al</AU>
<TI>Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage</TI>
<SO>Neurosurgery</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>2</NO>
<PG>269-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9482177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-SIGNET-2011" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="SIGNET 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-25 13:40:12 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews PJ, Avenell A, Noble DW, Campbell MK, Battison CG, Croal BL, et al</AU>
<TI>Randomised trial of glutamine and selenium supplemented parenteral nutrition for critically ill patients. Protocol Version 9, 19 February 2007 known as SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-25 13:39:49 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andrews PJ, Avenell A, Noble DW, Campbell MK, Croal BL, Simpson WG et al</AU>
<TI>Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d1542</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews PJ, Avenell A, and the SIGNET Trial Group</AU>
<TI>Results of The SIGNET Trial - a randomised controlled trial of glutamine and/or selenium supplemented parenteral nutrition in critical illness</TI>
<SO>Proceedings of the Nutrition Society</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>OCE2</NO>
<PG>E170</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-14 16:40:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews PJ, Simpson WG and the SIGNET Trial group</AU>
<TI>Results of the SIGNET Trial - a randomised controlled trial of glutamine and/or selenium supplemented parenteral nutrition in critical illness</TI>
<SO>Clinical Nutrition Supplements</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>2</NO>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>Andrews PJ</AU>
<TI>Randomised trial of glutamine and selenium supplemented parenteral nutrition (PN) for critically ill patients</TI>
<SO>http://www.isrctn.com/ISRCTN87144826</SO>
<YR>(accessed 21 October 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-12-22 13:35:12 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valenta-2011" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Valenta 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-23 22:21:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodska H, Kazda A, Valenta J, Hendl J</AU>
<TI>Effect of high-dose selenium substitution on selected laboratory parameters and prognosis in critically ill patients</TI>
<SO>Critical Care</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>S62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:21:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodska H, Kazda A, Valenta J, Stach Z, Hendl J, Pelinkova K, et al</AU>
<TI>Laboratory monitoring during high dose selenium substitution in critically ill patients</TI>
<SO>Clinical Chemistry and Laboratory Medicine</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>S396</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:21:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodska H, Kazda A, Valenta J, Stach Z, Hendl J, Pelinkova K</AU>
<TI>High dose of selenium in critically ill</TI>
<SO>Clinical Nutrition Supplements</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>2</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:22:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodska H, Kohout P, Malickova K, Kazda A, Valenta J</AU>
<TI>Influence of high selenium doses supplementation on markers of nutritional status</TI>
<SO>Clinical Nutrition Supplements</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>2</NO>
<PG>115</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:22:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazda A, Brodska H, Valenta J, Vinglerova M, Hendl J, Stach Z, et al</AU>
<TI>Selenium and its substitution in critically ill patients</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>S79-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valenta J, Brodska H, Drabek T, Hendl J, Kazda A</AU>
<TI>High-dose selenium substitution in sepsis: a prospective randomized clinical trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>5</NO>
<PG>808-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 22:23:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valenta J, Brodska H, Kazda A, Stach Z, Hendl J, Pelinkova K</AU>
<TI>Effect of high-dose selenium substitution on selected laboratory parameters and prognosis in critically ill patients</TI>
<SO>Critical Care</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>S62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamaguchi-1998" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Yamaguchi 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al for the Ebselen Study Group</AU>
<TI>Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9445321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmermann-1997" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Zimmermann 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann T, Albrecht S, Kühne H, Vogelsang U, Grützmann R, Kopprasch S</AU>
<TI>Selenium administration in patients with sepsis syndrome. A prospective randomized study</TI>
<TO>Selensubstitution bei sepsispatienten. Eine prospektiv randomisierte studie</TO>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>3-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9417494"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann T, Albrecht S, von Gagern G</AU>
<TI>Molecular-biology studies of a multicenter phase III study (SIC-study)</TI>
<TO>Molekularbiologische untersuchungen zur multizentrischen phase-III-studie (SIC-studie)</TO>
<SO>Medizinische Klinik</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>Suppl 3</NO>
<PG>58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1998" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Berger 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Spertini F, Shenkin A, Wardle C, Wiesner L, Schindler C, et al</AU>
<TI>Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1998</YR>
<VL>68</VL>
<NO>2</NO>
<PG>365-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9701195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2004a" MODIFIED="2015-07-25 14:53:47 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Berger 2004a" YEAR="2004">
<REFERENCE MODIFIED="2015-07-25 14:53:47 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger M, Binnert C, Baines M, Raffoul W, Cayeux M, Chiolero R, et al</AU>
<TI>Trace element supplements influence protein metabolism and tissue levels after major burns</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2004b" MODIFIED="2015-07-23 23:05:01 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2004b" YEAR="2004">
<REFERENCE MODIFIED="2015-07-23 23:05:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger M, Soguel L, Schindler C, Revelly J, Chiolero R</AU>
<TI>Antioxidant micronutrients after complex cardiac surgery and clinical evolution? Preliminary data</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>175</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2005a" MODIFIED="2015-07-23 23:05:56 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2005a" YEAR="2005">
<REFERENCE MODIFIED="2015-07-23 23:05:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Eggimann P, Revelly JP, Raffoul W, Shenkin A, Chiolero R</AU>
<TI>Trace element supplements are associated with fewer nosocomial pneumonia after major burns</TI>
<SO>Intensive Care Medicine</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 23:05:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Eggimann P, Revelly JP, Raffoul W, Shenkin A, Chiolero RL</AU>
<TI>Selenium supplements reduce the incidence of nosocomial pneumonia after major burns</TI>
<SO>Clinical Nutrition</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>614</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2005b" MODIFIED="2015-07-23 23:06:31 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2005b" YEAR="2005">
<REFERENCE MODIFIED="2015-07-23 23:06:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Soguel L, Pinget C, Revelly JP, Schindler C, Chiolero RL</AU>
<TI>Antioxidant supplements modulate clinical course after complex cardiac surgery, and major trauma</TI>
<SO>Intensive Care Medicine</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-23 23:06:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger MM, Soguel L, Pinget C, Revelly JP, Schindler C, Chiolero RL</AU>
<TI>Antioxidant supplements modulate clinical course after complex cardiac surgery, major trauma, and subarachnoid haemorrhage</TI>
<SO>Clinical Nutrition</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>616</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2008" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Berger 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger M, Soguel L, Shenkin A, RevellyJP, Pinget C, Baines M, et al</AU>
<TI>Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients</TI>
<SO>Critical Care</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>4</NO>
<PG>R101</PG>
<IDENTIFIERS MODIFIED="2014-09-08 19:02:28 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-09-08 19:02:28 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1186/cc6981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00f6_rner-1997" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Börner 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Börner J, Zimmermann T, Albrecht S, Roesner D</AU>
<TI>Selenium administration in severe inflammatory surgical diseases and burns in childhood</TI>
<TO>Selensubstitution bei schweren entzündlichen chirurgischen krankheitsbildern sowie verbrennungen un verbrühungen in kindesalter</TO>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>17-9</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:04:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:04:07 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="9417488"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collier-2008" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Collier 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collier BR, Giladi A, Dossett LA, Dyer L, Fleming SB, Cotton BA</AU>
<TI>Impact of high-dose antioxidants on outcomes in acutely injured patients</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>4</NO>
<PG>384-8</PG>
<IDENTIFIERS MODIFIED="2014-09-08 19:11:23 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-09-08 19:11:23 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1177/0148607108319808 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiessling-2006" MODIFIED="2015-07-23 23:09:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kiessling 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-07-23 23:09:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiessling AH, Isgro F, Skuras JA, Kammerer I, Lehmann A, Saggau W</AU>
<TI>Selenium application in intensive care medicine</TI>
<SO>Intensive Care Medicine</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>Suppl 1</NO>
<PG>89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porter-1999" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Porter 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porter JM, Ivatury RR, Azimuddin K, Swami R</AU>
<TI>Antioxidant therapy in the prevention of organ dysfunction syndrome and infectious complications after trauma: early results of a prospective randomized study</TI>
<SO>American Surgeon</SO>
<YR>1999</YR>
<VL>65</VL>
<NO>5</NO>
<PG>478-83 (Erratum in American Surgeon 1999;65:902)</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:05:22 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:05:22 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="10231223"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-REDOXS-2011" MODIFIED="2015-07-25 13:44:18 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="REDOXS 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-25 13:44:18 +0100" MODIFIED_BY="Mikkel Allingstrup" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al</AU>
<TI>A randomized trial of glutamine and antioxidants in critically ill patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>16</NO>
<PG>1489-97</PG>
<IDENTIFIERS MODIFIED="2015-07-25 13:44:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 13:44:18 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1056/NEJMoa1212722"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stoppe-2010" MODIFIED="2015-07-23 23:13:23 +0100" MODIFIED_BY="[Empty name]" NAME="Stoppe 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-23 23:13:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stoppe C, Wildenhues A, Metzelder S, Schalte G, Menon AK, Rossaint R, et al</AU>
<TI>The effects of high dose selenium supplementation on perioperative systemic inflammation in patients undergoing open heart surgery</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>Suppl 2</NO>
<PG>S316</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiele-1997" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Thiele 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiele R, Wagner D, Gassel M, Winnefeld K, Pleissner J, Pfeifer R</AU>
<TI>Selenium substitution in acute myocardial infarct</TI>
<TO>Selensubstitution bei akutem myokardinfarkt</TO>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>26-8</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:05:53 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:05:53 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="9417492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uden-1990" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Uden 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uden S, Bilton D, Nathan L, Hunt LP, Main C, Braganza JM</AU>
<TI>Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>4</NO>
<PG>357-71</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:06:02 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:06:02 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE=" 2103755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watters-2002" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Watters 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watters JM, Vallerand A, Kirkpatrick SM, Abbott HE, Norris S, Wells G, et al</AU>
<TI>Limited effects of micronutrient supplementation on strength and physical function after abdominal aortic aneursymectomy</TI>
<SO>Clinical Nutrition</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>321-7</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:06:13 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:06:13 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="12135593"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollschl_x00e4_ger-1997" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Wollschläger 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollschläger S, Ludwig K, Meissner D, Porst H</AU>
<TI>Effect of selenium administration on various laboratory parameters in patients with acute pancreatitis</TI>
<TO>Einfluß einer selensubstitution auf verschiedene laborparameter bei patienten mit akuter pankreatitis</TO>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>22-4</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:06:21 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:06:21 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="9417490"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Geoghegan-2009" MODIFIED="2015-07-23 23:02:24 +0100" MODIFIED_BY="[Empty name]" NAME="Geoghegan 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-23 23:02:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geoghegan M, Eaton S, Mandersloot G, Healy M, McAuley DF, Rayman MP, et al</AU>
<TI>Selenium decreases lipid peroxidation in critically-ill patients with sub-arachnoid haemorrhage</TI>
<SO>Clinical Nutrition Supplements</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>2</NO>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamaguchi-2003" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Yamaguchi 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yamaguchi T, for Ebselen Study Group</AU>
<TI>Phase III trial of Ebselen (abstract)</TI>
<SO>American Stroke Association 28th International Stroke Conference, 2003 February 13 -15; Phoenix, Arizona</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-SEREAL-2012" MODIFIED="2014-11-03 11:19:54 +0000" MODIFIED_BY="Mikkel Allingstrup" NAME="SEREAL 2012" YEAR="2012">
<IDENTIFIERS MODIFIED="2014-10-21 11:34:16 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-21 11:34:16 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="CTG" VALUE="NCT01601938"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SISPCT" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="SISPCT" YEAR="">
<REFERENCE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Reinhart K</AU>
<TI>Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00832039</SO>
<IDENTIFIERS MODIFIED="2014-12-09 18:03:18 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-12-09 18:03:18 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="OTHER" VALUE="NCT00832039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-20 07:20:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-20 07:20:18 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Angstwurm-2006" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Angstwurm 2006" TYPE="JOURNAL_ARTICLE">
<AU>Angstwurm MW, Gaertner R</AU>
<TI>Practicalities of selenium supplementation in critically ill patients</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>3</NO>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASPEN" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="ASPEN" TYPE="OTHER">
<TI>American Society for Parenteral and Enteral Nutrition</TI>
<SO>https://www.nutritioncare.org/</SO>
<YR>(accessed 21 October 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2007" MODIFIED="2015-07-25 10:28:59 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Berger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Berger M, Baines M, Raffoul W, Benathan M, Chiolero R, Reeves C,</AU>
<TI>Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations.</TI>
<SO>The American journal of clinical nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<PG>1293 - 300</PG>
<IDENTIFIERS MODIFIED="2015-07-25 10:28:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 10:28:59 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="17490965"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2015-07-23 22:31:29 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2014-10-17 13:32:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18824466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bulger-2001" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bulger 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bulger EM, Maier RV</AU>
<TI>Antioxidants in critical illness</TI>
<SO>Archives of Surgery</SO>
<YR>2001</YR>
<VL>136</VL>
<NO>10</NO>
<PG>1201-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11585516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS MODIFIED="2014-10-17 11:52:38 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-17 11:52:38 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="MEDLINE" VALUE="15161896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ESPEN" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="ESPEN" TYPE="OTHER">
<TI>European Society for Clinical Nutrition and Metabolism</TI>
<SO>http://www.espen.org/</SO>
<YR>(Accessed 21 October 2014)</YR>
<IDENTIFIERS MODIFIED="2014-11-03 12:36:20 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
</REFERENCE>
<REFERENCE ID="REF-Geoghegan-2006" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Geoghegan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Geoghegan M, McAuley D, Eaton, Powell-Tuck J</AU>
<TI>Selenium in critical illness</TI>
<SO>Current Opinion in Critical Care</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>136-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giladi-2011" MODIFIED="2015-07-25 10:49:29 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Giladi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Giladi A, Dossett L, Fleming S, Abumrad N, Cotton B.</AU>
<TI>High-dose antioxidant administration is associated with a reduction in post-injury complications in critically ill trauma patients</TI>
<SO>Injury</SO>
<YR>2011</YR>
<VL>42</VL>
<PG>78 - 82</PG>
<IDENTIFIERS MODIFIED="2015-07-25 10:49:29 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 10:49:29 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="20149369"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heyland-2005" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Heyland 2005" TYPE="JOURNAL_ARTICLE">
<AU>Heyland DK, Dhaliwal R, Suchner U, Berger MM</AU>
<TI>Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient</TI>
<SO>Intensive Care Mediicine</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>3</NO>
<PG>327-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15605227"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539&#8211;58</PG>
<IDENTIFIERS MODIFIED="2015-01-30 17:54:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-17 12:51:53 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="MEDLINE" VALUE="12111919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Intervention<I>s</I> [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2015-01-30 17:54:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-12-09 18:13:38 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1002/9780470712184"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005" MODIFIED="2015-10-20 07:20:18 +0100" MODIFIED_BY="[Empty name]" NAME="Hozo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hozo SP, Djulbegovic B, Hozo I</AU>
<TI>Estimating the mean and variance from the median, range, and the size of a sample</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2014-11-15 11:20:47 +0000" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-11-15 11:20:47 +0000" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="15840177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huang-2013" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Huang 2013" TYPE="JOURNAL_ARTICLE">
<AU>Huang TS, Shyu YC, Chen HY, Lin LM, Lo CY, Yuan SS, et al</AU>
<TI>Effect of parenteral selenium supplementation in critically ill patients: a systematic review and meta-analysis</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>1</NO>
<PG>e54431</PG>
<IDENTIFIERS MODIFIED="2014-10-17 12:03:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-17 12:03:25 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1371/journal.pone.0054431"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2000" MODIFIED="2015-07-23 22:39:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL, Williamson PR</AU>
<TI>Bias in meta-analysis due to outcome variable selection within studies</TI>
<SO>Journal of the Royal Statistical Society Series</SO>
<YR>2000</YR>
<VL>49</VL>
<PG>359-70</PG>
<IDENTIFIERS MODIFIED="2014-10-17 11:57:38 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-17 11:57:38 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="MEDLINE" VALUE="11122498"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jennett-1975" MODIFIED="2015-07-23 22:40:00 +0100" MODIFIED_BY="[Empty name]" NAME="Jennett 1975" TYPE="JOURNAL_ARTICLE">
<AU>Jennett B, Bond M</AU>
<TI>Assessment of outcome after severe brain damage. A practical scale</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>480-4</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:19:59 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:19:59 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="46957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lan-1983" MODIFIED="2015-07-23 22:40:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lan KKG, DeMets DL</AU>
<TI>Discrete sequential boundaries for clinical trials</TI>
<SO>Biometrika</SO>
<YR>1983</YR>
<VL>70</VL>
<PG>659-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landucci-2014" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Landucci 2014" TYPE="JOURNAL_ARTICLE">
<AU>Landucci F, Mancinelli P, De Gaudio AR, Virgili G</AU>
<TI>Selenium supplementation in critically ill patients: a systematic review and meta-analysis</TI>
<SO>Journal of Critical Care</SO>
<YR>2014</YR>
<VL>29</VL>
<NO>1</NO>
<PG>150-6</PG>
<IDENTIFIERS MODIFIED="2014-10-17 08:32:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-17 08:32:55 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1016/j.jcrc.2013.08.017"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manzanares-2009" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Manzanares 2009" TYPE="JOURNAL_ARTICLE">
<AU>Manzanares W, Hardy G</AU>
<TI>Selenium supplementation in the critically ill: posology and pharmacokinetics</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>3</NO>
<PG>273-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manzanares-2012" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Manzanares 2012" TYPE="JOURNAL_ARTICLE">
<AU>Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK</AU>
<TI>Antioxidant micronutrients in the critically ill: a systematic review and meta-analysis</TI>
<SO>Critical Care</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>2</NO>
<PG>R66</PG>
<IDENTIFIERS MODIFIED="2014-10-17 08:37:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2014-10-17 08:37:03 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="DOI" VALUE="10.1186/cc11316."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2015-07-25 13:56:32 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz K, Montori V, Gøtzsche P, Devereaux P et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.</TI>
<SO>International journal of surgery</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>28 - 55</PG>
<IDENTIFIERS MODIFIED="2015-07-25 13:53:57 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 13:53:57 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="22036893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parnham-2000" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Parnham 2000" TYPE="JOURNAL_ARTICLE">
<AU>Parnham M, Sies H</AU>
<TI>Ebselen: prospective therapy for cerebral ischaemia</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>3</NO>
<PG>607-19</PG>
<IDENTIFIERS MODIFIED="2014-12-12 18:20:34 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2014-12-12 18:20:34 +0000" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="11060699"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1997" MODIFIED="2015-07-23 22:46:42 +0100" MODIFIED_BY="[Empty name]" NAME="Pogue 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pogue JM, Yusuf S</AU>
<TI>Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>580-93</PG>
<IDENTIFIERS MODIFIED="2014-10-17 13:32:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="9408720"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rayman-2012" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rayman 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rayman M</AU>
<TI>Selenium and human health</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>379</VL>
<PG>1256 - 68</PG>
<IDENTIFIERS MODIFIED="2015-07-25 10:03:52 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER MODIFIED="2015-07-25 10:03:52 +0100" MODIFIED_BY="Mikkel Allingstrup" TYPE="PUBMED" VALUE="22381456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.3" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="RevMan 5.3" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3.5</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS MODIFIED="2014-10-17 12:34:32 +0100" MODIFIED_BY="Mikkel Allingstrup"/>
</REFERENCE>
<REFERENCE ID="REF-Sattar-1997" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sattar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sattar N, Eatock F, Fell GS, O'Reilly D</AU>
<TI>Selenium: an acute-phase reactant?</TI>
<SO>Annals of Clinical Biochemistry</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>Pt 4</NO>
<PG>437-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9247681"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shah-1989" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Shah 1989" TYPE="JOURNAL_ARTICLE">
<AU>Shah S, Vanclay F, Cooper B</AU>
<TI>Predicting discharge status at commencement of stroke rehabilitation</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>6</NO>
<PG>766-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2728043"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2015-07-23 22:50:52 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2014-10-17 13:32:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18824467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2015-07-25 13:57:55 +0100" MODIFIED_BY="Mikkel Allingstrup" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA). CTU (Copenhagen Trial Unit). 2011</TI>
<SO>http://www.ctu.dk/TSA/files/tsa_manual.pdf</SO>
<YR>(accessed 21 Oct 2014)</YR>
<PG>1-118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trial-Sequential-Analysis-_x0028_TSA_x0029_" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Trial Sequential Analysis (TSA)" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis. Copenhagen Trial Unit (CTU)</TI>
<YR>2011</YR>
<PB>Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark. www.ctu.dk/tsa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2015-07-23 22:55:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2014-10-17 13:32:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="18083463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2014-10-17 13:32:47 +0100" MODIFIED_BY="Mikkel Allingstrup">
<IDENTIFIER TYPE="MEDLINE" VALUE="20042080"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Avenell-2002" MODIFIED="2015-07-23 22:27:09 +0100" MODIFIED_BY="[Empty name]" NAME="Avenell 2002" TYPE="COCHRANE_PROTOCOL">
<AU>Avenell A, Noble DW, Barr J, Engelhardt T</AU>
<TI>Selenium supplementation for critically ill adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>3</YR>
<NO>2002</NO>
<IDENTIFIERS MODIFIED="2015-01-28 17:25:40 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-01-28 17:25:38 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD003703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Avenell-2004" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NAME="Avenell 2004" TYPE="COCHRANE_REVIEW">
<AU>Avenell A, Noble DW, Barr J, Engelhardt T</AU>
<TI>Selenium supplementation for critically ill adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003703.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Angstwurm-1999">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states stratified randomization only<BR/>Assessor blinding: states open label<BR/>Intention to treat (ITT): carried out<BR/>Lost to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: ICU, Klinikum Innenstadt, University of Munich, Germany<BR/>Period of trial: recruitment March 1995 to August 1996<BR/>42 patients<BR/>Inclusion criteria: APACHE score &#8805; 15, and clinical and laboratory signs of new systemic inflammatory response syndrome (SIRS) according to sepsis criteria (American College of Chest Physicians/Society of Critical Care Medicine), first 24 hours after admission<BR/>Exclusion criteria: age &lt; 18 years, pregnancy, after cardiopulmonary resuscitation, severe gastrointestinal bleeding, trauma, surgery, chronic renal failure, refusal to participate<BR/>Sex: 29 males, 13 females<BR/>Age: mean age 56 years (range 18 to 83 years)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: from day of admission to intensive care for additional supplementation for nine days</P>
<OL>
<LI>Continuous intravenous sodium selenite (535 mcg selenium for 3 days, 285 mcg selenium for 3 days, 155 mcg selenium for 3 days, 35 mcg selenium for remainder of total treatment time; and standard parenteral nutrition including glutamine 20 g/L</LI>
<LI>Continuous placebo of saline and intravenous 35 mcg selenium as sodium selenite, and standard parenteral nutrition including glutamine 20 g/L</LI>
</OL>
<P>Allocated: 21/21<BR/>Assessed: 21/21<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: until discharge</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Number of days on a ventilator</LI>
<LI>Length of hospital stay</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Request for further details of interventions sent 24 October 2003, reply received 17 November 2003.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Angstwurm-2007">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: performed<BR/>ITT: not performed<BR/>Lost to follow-up: reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 11 independent German ICUs<BR/>Period of trial: enrolment December 1999 to October 2004<BR/>249 patients<BR/>Inclusion criteria: men and women &gt; 18 years with APACHE III score (22) &gt; 70 and at least two of the following criteria: rectal body temperature &gt; 38°C or hypothermia &lt; 36°C, heart rate &gt; 90 per minute, respiratory frequency &gt; 20 per minute and PaCO2 &lt; 32 mmHg (&lt; 4.3 kPa), leucocytes &gt; 12 000/µL or &lt; 4 000/µL or &gt; 10% immature leucocytes, decrease of platelet count &gt; 50 % within the first 24 hrs or platelets &lt; 150,000/µL at admission; admission into the trial after diagnosis within 24 hours; beginning of treatment within 1 hour after inclusion.<BR/>Exclusion criteria: pregnancy; missing informed consent of patient or relative/intimate friend; withdrawal of informed consent after inclusion into trial; participation in any clinical trial within last 30 days; prior participation in this clinical trial; cerebral injury due to hypoxia after cardiopulmonary resuscitation; primary concomitant disease with expected high mortality within 2 months; not for resuscitation; malignant primary disease as cause of systemic inflammatory response syndrome or sepsis, e.g. agranulocytosis as result of chemotherapy or idiopathic bone marrow aplasia; haemorrhagic - necrotising pancreatitis without infectious complications.<BR/>Sex: 162 males, 76 females<BR/>Age: 64.6 years (SD 14.0)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: admission into trial after diagnosis within 24 hours, trial treatment beginning within 1 hour after inclusion</P>
<OL>
<LI>48 mL vial as bolus intravenous injection over 30 minutes providing 1000 mcg sodium selenite, followed by continuous infusion of 2 mL/hour over 24 hours for 14 days, total dose 15,000 mcg selenium. Allowed selenium from other preparations of up to 100 mcg/day.</LI>
<LI>Matching placebo of 0.9% sodium chloride give as same regimen. Allowed selenium from other preparations of up to 100 mcg/day.</LI>
</OL>
<P>Allocated: unclear<BR/>Assessed: 116/122<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days</P>
<P>Main outcomes:</P>
<UL>
<LI>28 day mortality</LI>
<LI>Participants with new infections</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Number of days on a ventilator</LI>
<LI>Length of ICU stay</LI>
<LI>Participants with adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Email From Professor Gärtner on 8 August 2006 provided further details on participants with infections, length of ventilation, numbers randomized to each group, and details of the randomization process.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-2001">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: concealed<BR/>Assessor blinding: states double-blinded but no further details<BR/>ITT: performed<BR/>Lost to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: surgicalICU of the Central Hospitalier Universitaire Vaudois, Lausanne, Switzerland<BR/>Period of trial: before 2000<BR/>21 patients<BR/>Inclusion criteria: severe multiple injury (injury Severity Score, ISS, &gt; 15) involving at least two body systems, pathophysiological changes requiring ICU support, age 18 to 75 years, admission within 24 hours of injury<BR/>Exclusion criteria: pre-existing renal or hepatic failure, foreseeable imminent death, no informed consent, documented hypothyroidism prior to accident<BR/>Sex: 15 males, 6 females<BR/>Age: age range 18 to 74 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: from day of admission for five days</P>
<OL>
<LI>Slow intravenous infusion over 24 hours of 500 mcg selenium as sodium selenite/day</LI>
<LI>Infusion vehicle over 24 hours</LI>
<LI>Slow intravenous infusion over 24 hours of 500 mcg selenium/day and 13 mg zinc/day, 150 mg alpha-tocopherol in 5 ml 10% lipid emulsion (Lipovenös, Fresenius, Stans, Switzerland) as slow injection once daily upon initiation of intravenous infusion (data for this group not used in this review)</LI>
</OL>
<P>Allocated: 9/12/11<BR/>Assessed: 9/12/11<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: appears followed up until died or left hospital, maximum length of stay 249 days</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Numbers of patients with infection (defined as requiring antibiotics)</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Number of days on a ventilator</LI>
<LI>Length of ICU stay</LI>
<LI>Length of hospital stay</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>ITT data taken from paper in Nutrition Research</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Forceville-2007">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: stratified in each centre by blocks of four, sequentially numbered identical boxes provided to the investigator by the pharmacist, following the order of the randomization list</P>
<P>Assessor blinding: states double-blind</P>
<P>ITT: performed</P>
<P>Lost to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 7 ICUs in France</P>
<P>Period of trial: randomization from 8 February 2002 to 12 March 2004</P>
<P>Inclusion criteria: severe documented infection (one or more of positive culture or Gram stain of normally sterile fluid, clinical focus of infection, nosocomial infection; need for mechanical ventilation; severe septic shock (circulatory failure requiring at least 1 L in previous 24 hours and treated for at least one hour with &gt;15 mcg/kg/min dopamine or &gt; 0.2 mcg/kg/min epinephrine or norepinephrine corresponding to class 4 of cardiovascular failure of Sequential Organ Failure Assessment score; Simplified Acute Physiologic Score II of 25 or more; consent from patients or representatives</P>
<P>Exclusion criteria: pregnancy, end-stage chronic disease, limitation of care in place, preliminary circulatory failure, shock due to urinary infection without bacteraemia, peritonitis due to peritoneal dialysis or trauma, participant in another trial</P>
<P>Sex: 38 males, 22 females</P>
<P>Age: selenium 66 years (SD 14), placebo 69 years (SD 12)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: unclear when started, given for 10 days</P>
<OL>
<LI>4000 mcg selenium as intravenous sodium selenite (in 192 mL saline) over 24 hrs, then 1000 mcg selenium as sodium selenite (in 48 mL saline) over 24 hrs for 9 days</LI>
<LI>Matching saline placebo for 10 days</LI>
</OL>
<P>Allocated: 31/29</P>
<P>Assessed: 31/29</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: one year after randomization</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Participants with infection</LI>
<LI>Length of stay in an ICU</LI>
<LI>Length of stay in hospital</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-03 16:01:04 +0000" MODIFIED_BY="Jane Cracknell">
<P>The trial is registered at <A HREF="http://ClinicalTrials.gov.">ClinicalTrials.gov.</A> There is complete agreement between the information registered in the database and the results in the article.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Janka-2013">
<CHAR_METHODS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: Odd or even date of admission to ICU</P>
<P>Assessor blinding: no details, prospective observational trial</P>
<P>ITT: no details.<BR/>Lost to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: The 1st Clinic of Anaesthesiology and Intensive Care Medicine, University Hospital of Louis Pasteur in Kos&#780;ice, Slovak Republic.</P>
<P>Period of trial: January 2008. No end date stated.</P>
<P>72 patients<BR/>Inclusion criteria: patients who developed sepsis, severe sepsis or septic shock during hospitalisation, APACHE 19-40 after admission.</P>
<P>Exclusion criteria: APACHE &lt; 19</P>
<P>Sex: 49 males, 23 females<BR/>Age: mean age 53 years, 23 to 79</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: immediately after admission to ICU department, no details.</P>
<P>Trial intervention was for a maximum of six days.</P>
<P>Case: continuous infusion, sodium selenite pentahydrate at 750 mg/day for 6 days</P>
<P>Control: continuous infusion, NaCl 50 mL/day for 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days</P>
<P>Main outcomes:</P>
<UL>
<LI>28-day mortality</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>APACHE II score</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Kuklinski-1991">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:57 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: not reported<BR/>ITT: carried out<BR/>Lost to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: hospital, Rostock, Germany<BR/>Period of trial: before 1991<BR/>17 patients<BR/>Inclusion criteria: contrast CT scan showed pancreatic necrosis, &lt; 72 hours since onset of pancreatitis<BR/>Exclusion criteria: mild pancreatitis<BR/>Sex: all male<BR/>Age: range 28 to 65 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 13:10:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: 28 days</P>
<OL>
<LI>Intravenous 500 mcg sodium selenite daily duration unclear (Selenase pro injectione, GN PHARM, Arzneimittel GmbH, Stuttgart)</LI>
<LI>No treatment</LI>
</OL>
<P>Allocated: 8/9<BR/>Assessed: 8/9<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:57 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up:</P>
<P>Main outcome:</P>
<UL>
<LI>Mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:26:57 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Request for further details on dose of selenium given sent 20 October 2003. Letter returned as author no longer at address in publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Lindner-2004">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: not reported<BR/>ITT: not reported<BR/>Lost to follow-up: details provided<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: medical centre, Chemnitz, Germany<BR/>Period of trial: enrolment January 1997 to November 1998<BR/>70 patients<BR/>Inclusion criteria: severe acute pancreatitis managed on medical wards, severe abdominal pain, 3-fold increase of amylase and lipase, onset within 72 hours<BR/>Exclusion criteria: none given<BR/>Sex: 39 males, 28 females (completers)<BR/>Age: median 50 to 52 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: start unclear, given until discharged</P>
<OL>
<LI>Day 1 2000 mcg selenium as sodium selenite, days 2 to 5 1000 mcg/d, day 6 until discharged 300 mcg/d</LI>
<LI>0.9% sodium chloride placebo</LI>
</OL>
<P>Allocated: 35/35<BR/>Assessed: 32/35<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: until discharge</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Number of patients with infectious complications (sepsis)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Manzanares-2011">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: states participants blinded<BR/>ITT: not carried out<BR/>Lost to follow-up: not complete, four patients excluded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: single centre, university hospital ICU, Montevideo, Uruguay<BR/>Period of trial: randomization Decmber 2006 to January 2008<BR/>35 patients<BR/>Inclusion criteria: patients with systemic inflammatory response and APACHE II score &#8805; 15 and predicted mechanical ventilation &gt; 48 hours.<BR/>Exclusion criteria: age &lt; 18 years, pregnancy, brain injury after cardiopulmonary arrest, malignant disease, immune deficiency, chronic renal failure, participation in another trial, limitation of care, refused consent.<BR/>Sex: 15 males, 16 females<BR/>Age: mean age 58 (17 SD) years for 15 in selenite group, 54 (SD 17) for 16 in placebo group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: randomized within first 24 hours of ICU admission</P>
<OL>
<LI>Intravenous selenium 2000 mcg (as selenious acid) bolus loading dose over 2 hours within 2 hours of enrolment; thereafter 1600 mcg/d in 240 mL 0.9% NaCl for 10 days</LI>
<LI>Matching placebo 0.9% NaCl only for 10 days</LI>
</OL>
<P>Allocated: 16/19<BR/>Assessed: 15/16</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: duration of hospital stay</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality at in intensive care and hospital</LI>
<LI>Infections</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Days on ventilator</LI>
<LI>Length of ICU stay</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We emailed Dr Manzanares 27 April 2011 for details of adverse events and deaths, who provided information on 28 April 2011</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Mishra-2007">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: states double-blind<BR/>ITT: not reported<BR/>Lost to follow-up: no details provided<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: ICU, Liverpool, UK<BR/>Period of trial: before 2002 to 2004<BR/>40 patients<BR/>Inclusion criteria: APACHE II score &gt; 15, clinical suspicion of infection and &gt; 1 organ dysfunction<BR/>Exclusion criteria: chronic renal failure, alcoholic liver disease, immunodeficiency<BR/>Sex: 19 males, 21 females<BR/>Age: mean age 66 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: within 24 hours of admission to intensive care and within 72 hours since diagnosis of sepsis, given until discharged</P>
<OL>
<LI>Intravenous selenium 470 mcg/day for 3 days, then 320 mcg/day for 3 days, then 160 mcg/day for 3 days, and 30 mcg/day thereafter</LI>
<LI>30 mcg/day</LI>
</OL>
<P>Allocated: 18/22<BR/>Assessed: 18/22 for mortality<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality at 28 days</LI>
<LI>Infections</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Length of ICU stay</LI>
<LI>Renal replacement therapy</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Montoya-2009">
<CHAR_METHODS MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized in sealed envelopes</P>
<P>Assessor blinding: states double-blind in but no further details<BR/>ITT: no details<BR/>Lost to follow-up: None</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: a single ICU, no further details</P>
<P>Period of trial: October 2007 to February 2008</P>
<P>68 patients<BR/>Inclusion criteria: diagnosis of sepsis, age over 18 years</P>
<P>Exclusion criteria: chronic pro-inflammatory state, pregnant patients and patients receiving total parenteral nutrition.</P>
<P>Sex: 38 males, 30 females<BR/>Age: mean age 66 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: no details</P>
<P>Trial intervention was for 10 days</P>
<P>Case: 1000 &#956;g selenium the first day, 500 &#956;g the second day and 200 &#956;g/day until the end of the trial.</P>
<P>Control: 100 &#956;g/day selenium up to the end of the trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: no details</P>
<P>Main outcomes:</P>
<UL>
<LI>SOFA score</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>APACHE score and mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-03 08:32:56 +0000" MODIFIED_BY="Mikkel Allingstrup"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Ogawa-1999">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized list but no further details<BR/>Assessor blinding: states double-blind but no further details<BR/>ITT: ITT for mortality only<BR/>Lost to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 28 Japanese neurosurgical and neurological units<BR/>Period of trial: recruitment June 1994 to November 1996<BR/>105 patients<BR/>Inclusion criteria: acute stroke with complete occlusion of the M1 (M2) portion of the middle cerebral artery (MCA) on cerebral angiography and no low-density area (LDA) in the MCA territory on computed tomography (CT), could start drug treatment within 12 hours of stroke<BR/>Exclusion criteria: distinct fresh LDA in the MCA territory on CT scans; stenosis or occlusion of trunk arteries, other than MCA; haemorrhagic stroke including subarachnoid haemorrhage; pregnancy; severe hepatorenal or metabolic disease<BR/>Sex: 67 males, 32 females<BR/>Age: mean age 66 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: started within 12 hours of middle cerebral artery occlusion, given for 14 days</P>
<OL>
<LI>Oral ebselen 150 mg twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
<LI>Oral placebo granules twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
</OL>
<P>Allocated: 48/57<BR/>Assessed: 48/57 for mortality<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 13:11:18 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 14 days</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Numbers of patients with infection</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Quality of life - Glasgow Outcome Scale</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Request for further details of denominators and infections sent 22 October 2003, but no reply received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Saito-1998">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized lists but no further details<BR/>Assessor blinding: states double-blind and blinded outcome assessment<BR/>ITT: performed<BR/>Lost to follow-up: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 84 Japanese neurosurgical units<BR/>Period of trial: enrolled November 1992 to April 1994<BR/>286 patients<BR/>Inclusion criteria: subarachnoid haemorrhage (SAH) from aneurysmal rupture within previous 96 hours, and SAH Hunt and Kosnik grade II to IV or World Federation of Neurosurgical Surgeons grade I to IV at admission<BR/>Exclusion criteria: pregnancy; age &lt; 20 years or &gt; 71 years; major cardiopulmonary, hepatorenal or metabolic disease; large intracerebral or intraventricular clots<BR/>Sex: 112 males, 174 females<BR/>Age: mean age 56 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: started within 96 hours of subarachnoid haemorrhage, given for 14 days</P>
<OL>
<LI>Oral ebselen 150 mg twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
<LI>Oral placebo granules twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
</OL>
<P>Allocated: 145/141<BR/>Assessed: 145/141<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 3 months</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Numbers of patients with meningitis, respiratory infection</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Quality of life - Glasgow Outcome Scale</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Request for further details of unpublished trial mentioned in main trial report, and numbers of patients with infections sent 21 October 2003, but no reply received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-SIGNET-2011">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: remote telephone computer system generated random allocation</P>
<P>Assessor blinding: states double-blinded</P>
<P>ITT: performed</P>
<P>Lost to follow-up: none for mortality and infections</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 10 ICUs in Scotland (and associated high dependency units if also under the care of the same intensivists)<BR/>Period of trial: recruitment June 2004 to November 2008<BR/>502 patients<BR/>Inclusion criteria: expected to be on intensive care and high dependency units (levels 2 and 3 care) under the care of the ICU consultants for at least 48 hours, aged &#8805; 16 years or over, require parenteral nutrition and expected to have at least half of daily nutritional requirements given by that route<BR/>Exclusion criteria: pregnant women, people whose expected stay in the UK is &lt; six months, severe renal failure (creatinine clearance &lt; 10 mL/min and not on renal replacement therapy)<BR/>Sex: 304 males, 198 females<BR/>Age: mean age 63.8 (SD 14.9) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: from as soon as practicable by pharmacy, when decision made to commence parenteral nutrition for a maximum of 7 days, or until parenteral nutrition ceased</P>
<OL>
<LI>20.2 g glutamine in standard parenteral nutrition</LI>
<LI>500 mcg selenium as sodium selenite added to standard parenteral nutrition</LI>
<LI>Glutamine and in standard parenteral nutrition with 500mcg selenium as sodium selenite</LI>
<LI>Standard parenteral nutrition only</LI>
</OL>
<P>Volume of feed could be reduced for men &lt; 60 kg and women &lt; 70 kg<BR/>Allocated: 126/127/124/125<BR/>Assessed: 126/127/124/125</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 6 months after randomization</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Number of participants with infection in first 14 days (all clinically suspected, and all Centers for Disease Control and Prevention criteria confirmed infections)</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Length of stay in an ICU</LI>
<LI>Length of hospital stay</LI>
<LI>Quality of life after discharge</LI>
<LI>Adverse events</LI>
<LI>Economic outcomes</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Alison Avenell and David Noble were SIGNET trial investigators. Data was extracted by their trial co-investigators John Barr and Tom Engelhardt. Funding was provided by Fresenius-Kabi and Oxford Nutrition. The trial is registered at The ISRCTN registry and the protocol is published. Except for minor changes regard to the number of primary endpoints, there is full agreement between registrars, protocol and the results in the article.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Valenta-2011">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: randomized according to date of birth</P>
<P>Assessor blinding: open label</P>
<P>ITT: not carried out</P>
<P>Lost to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: single centre, university hospital mixed ICU</P>
<P>Period of trial: March 2004 to April 2009</P>
<P>Inclusion criteria: over 18 years, admitted with systemic inflammatory response syndrome, sepsis, septic shock, SOFS score over 5</P>
<P>Exclusion criteria: expected hospital stay &lt; 5 days, persistent vegetative state after hypoxic brain injury or traumatic brain injury, pregnancy, participation in another clinical trial, failure to gain consent, patient with limited care (e.g. do not resuscitate advance directive on file)</P>
<P>Sex: 97 males, 53 females (of 150 assessed)</P>
<P>Age: mean 60 years (SD 16) selenium, 60 years (SD 15) control</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: day one for 5 to 14 days</P>
<OL>
<LI>1000 mcg selenium as sodium selenite in 100 mL 0.9% NaCl over 30 minutes through central venous catheter at 9am on first day, thereafter 500 mcg/day over 30 minutes</LI>
<LI>No placebo</LI>
</OL>
<P>Allocated: 93/89</P>
<P>Assessed: 75/75</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days</P>
<P>Main outcome:</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Dr Helena Brodska gave details of randomization and control group intervention on 27 April 2011</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Yamaguchi-1998">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized lists but no further details<BR/>Assessor blinding: states double-blinded but no further details<BR/>ITT: not carried out<BR/>Lost to follow-up: incomplete, two patients excluded<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: 68 Japanese neurological and neurosurgical units<BR/>Period of trial: recruitment June 1994 to December 1996<BR/>302 patients<BR/>Inclusion criteria: acute ischemics stroke, including thrombosis and embolism, by symptoms and CT scan; could receive drug treatment within 48 hours of onset<BR/>Exclusion criteria: transient ischaemic attacks; pregnancy; surgery interfering with the assessment of neurological function; previous stroke with residual neurological impairment; major cardiopulmonary, hepatic, renal or metabolic disease; haemorrhagic stroke<BR/>Sex: 189 males, 111 females<BR/>Age: mean age 65 years, range 22 to 85 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: started within 48 hours of stroke, given for 14 days</P>
<OL>
<LI>Oral ebselen 150 mg twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
<LI>Oral placebo granules twice daily given enterally as fine granules dispersed in water, gastric tube if disturbed consciousness</LI>
</OL>
<P>Allocated: 152/150<BR/>Assessed: 151/149<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 3 months</P>
<P>Main outcomes:</P>
<UL>
<LI>Mortality</LI>
<LI>Numbers of patients with respiratory infection</LI>
</UL>
<P>Other outcomes:</P>
<UL>
<LI>Quality of life - Glasgow Outcome Scale, modified Barthel Index</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Zimmermann-1997">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Method of randomization: states randomized but no further details<BR/>Assessor blinding: not reported<BR/>ITT: not reported<BR/>Lost to follow-up: not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Location: university hospital, Dresden, Germany<BR/>Period of trial: before 1997<BR/>40 patients<BR/>Inclusion criteria: systemic inflammatory response syndrome and organ failure<BR/>Exclusion criteria: none given<BR/>Sex: not given<BR/>Age: not given<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Timing of intervention: start unclear, given for 28 days</P>
<OL>
<LI>1000 mcg bolus of sodium selenite, thereafter 1000 mcg/24 hours as continuous intravenous infusion, for 28 days</LI>
<LI>No treatment</LI>
</OL>
<P>Allocated: 20/20<BR/>Assessed: ?20/?20<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Length of follow-up: 28 days<BR/>Main outcome:<BR/>Mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Request for details of denominators and infections sent 21 October 2003, but no reply received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-07-25 14:23:11 +0100" MODIFIED_BY="Mikkel Allingstrup" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT in adults with burns; selenium part of trace element supplement evaluated, which also contained copper and zinc</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT in adults with burns; selenium part of trace element supplement evaluated, which also contained copper and zinc</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT in adults with cardiac surgery; selenium part of antioxidant supplement evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-22 22:07:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-22 22:07:43 +0000" MODIFIED_BY="[Empty name]">
<P>Combined results of <LINK REF="STD-Berger-2004a" TYPE="STUDY">Berger 2004a</LINK> and <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT in adults with cardiac surgery, myocardial infarction, trauma or subarachnoid haemorrhage; selenium part of antioxidant supplement evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-08 19:00:37 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Berger-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-08 19:00:37 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium part of trace element supplement evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-B_x00f6_rner-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Not a RCT, not adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-08 19:12:11 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Collier-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-08 19:12:11 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium part of trace element supplement evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-30 11:54:52 +0000" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Kiessling-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-30 11:54:52 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>Trial terminated without publishing data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Porter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT of antioxidant therapy (including selenium) versus placebo in trauma patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-REDOXS-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Factorial RCT of parenteral and enteral glutamine, and antioxidants (parenterally as selenium 500 µg, and enteral selenium 300 µg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Stoppe-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Not a RCT, no outcomes relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Thiele-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Not a RCT, not critical care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uden-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, crossover trial of antioxidant therapy (including selenium) versus placebo in the prevention of recurrence of pancreatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Watters-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT of micronutrients (including selenium) versus placebo in patients undergoing elective aneurysmectomy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Wollschl_x00e4_ger-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Not a RCT, selenium supplementation in acute pancreatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Geoghegan-2009">
<CHAR_METHODS MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Patients with subarachnoid haemorrhage (grade 2 to 5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>1000 mcg/d versus 500 mcg/d versus no sodium selenite intravenously, on ICU to maximum of 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-14 16:56:58 +0100" MODIFIED_BY="[Empty name]">
<P>28 day mortality, APACHE II and SOFA scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We emailed author (m.geoghegan@qmul.ac.uk and pgsmd@qmul.ac.uk) on 21 October 2014 but received no answer</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-Yamaguchi-2003">
<CHAR_METHODS MODIFIED="2011-04-15 15:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-15 15:50:16 +0100" MODIFIED_BY="[Empty name]">
<P>394 patients with acute non-lacunar stroke (cardio-embolic or atherothrombotic infarction &lt; 24 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-15 15:50:16 +0100" MODIFIED_BY="[Empty name]">
<P>Ebselen 150 mg twice daily or placebo started within 24 hours of onset for 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-15 15:50:16 +0100" MODIFIED_BY="[Empty name]">
<P>Glasgow Outcome Scale three months post stroke, National Institute of Health Stroke Scale and Barthel Index scores at one and three months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We emailed the author (tyamaguchi-rtec@umin.ac.jp) on 21 October 2014 but did not receive an answer.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-SEREAL-2012">
<CHAR_STUDY_NAME MODIFIED="2014-09-29 20:13:40 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-07-25 06:27:05 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-29 20:15:27 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Not yet recruiting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Selenium: 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.</P>
<P>Placebo: 10 mL mixed with 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary outcomes:</P>
<UL>
<LI>28-day mortality</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>ICU length of stay</LI>
<LI>Mortality at hospital discharge,</LI>
<LI>Development of the new infection</LI>
<LI>Ventilator days</LI>
<LI>Renal replacement therapy days</LI>
<LI>Oxidative stress marker</LI>
<LI>Changes in severity scores</LI>
<LI>3-month mortality</LI>
<LI>Vasopressor days</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-09-29 20:19:36 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>September 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Professor Gil Joon Suh, <A HREF="mailto:suhgil%40snu.ac.kr?subject=NCT01601938,%20SNUHEM-SEREAL-12-0001,%20Selenium%20Replacement%20and%20Serum%20Selenium%20Level%20in%20Severe%20Sepsis%20and%20Septic%20Shock%20Patients">suhgil@snu.ac.kr</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Status of the trial has not been verified in more than two years after the expected end date on <A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>. We emailed author (<A HREF="mailto:suhgil%40snu.ac.kr?subject=NCT01601938,%20SNUHEM-SEREAL-12-0001,%20Selenium%20Replacement%20and%20Serum%20Selenium%20Level%20in%20Severe%20Sepsis%20and%20Septic%20Shock%20Patients">suhgil@snu.ac.kr</A>) on 21 October 2014 but received no answer.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" STUDY_ID="STD-SISPCT">
<CHAR_STUDY_NAME MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>
<LINK REF="STD-SISPCT" TYPE="STUDY">SISPCT</LINK>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-15 15:40:41 +0100" MODIFIED_BY="[Empty name]">
<P>1180 adult participants with severe sepsis or septic shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Factorial designed, randomized trial of placebo-controlled selenium (bolus 2000 mcg, then 1000 mcg daily as 24-hour infusion for up to 21 days) and procalcitonin guided antibiotic therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>Primary outcome:</P>
<UL>
<LI>28 days all-cause mortality</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>Mean total SOFA ( Sequential Organ Failure Assessment)-score, and SOFA subscores</LI>
<LI>90 days all-cause mortality</LI>
<LI>Frequency and duration of mechanical ventilation until day 90</LI>
<LI>Frequency and duration of renal replacement therapy until day 90</LI>
<LI>Frequency and duration of vasopressor support until day 90</LI>
<LI>Frequencies of adverse and severe adverse events</LI>
<LI>Clinical cure and microbiological cure on day 4, 7, 10, and 14 (*)</LI>
<LI>Duration of antibiotic therapy (*)</LI>
<LI>Costs of antibiotic therapy (*)</LI>
<LI>Duration until change of antibiotic therapy (*)</LI>
<LI>Antibiotic exposure days (*)</LI>
<LI>Days alive without antibiotics (*)</LI>
<LI>Frequency of antibiotic resistance (*)</LI>
<LI>ICU length of stay until day 90</LI>
<LI>Hospital length of stay until day 90</LI>
<LI>Number of surgical procedures for source control (*)</LI>
<LI>Number of diagnostic procedures for searching the focus of infection (*)</LI>
</UL>
<P>(*) Endpoints are for the procalcitonin intervention only</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-04-15 15:36:38 +0100" MODIFIED_BY="[Empty name]">
<P>2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-07-25 06:27:06 +0100" MODIFIED_BY="Mikkel Allingstrup">
<P>We obtained information from Frank Bloos via Frank.Bloos@med.uni-jena.de on21 October 2014, the same day we emailed him. The trial group is currently writing the manuscript for publication and does not want to reveal data at this time. Publication is estimated to in 2015.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-04-15 15:36:51 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:02 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>Patients were stratified randomly into two groups. No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:51:59 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Odd or even date of admission to ICU</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:16 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:53:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>Patients were randomized with the use of separate randomization lists balanced for each participating centre. No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-22 13:49:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>A remote telephone computer system generated random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>States, separate balanced randomized lists for each participating centre, but no further details<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Randomized according to date of birth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:04 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>States separate randomization lists balanced for each participating centre, but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:47 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>States randomized but no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:03 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:56 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>Concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:51:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:00 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:18 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Not stated </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:28 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:39 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:53:01 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:53:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:01 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P> State, before code opening patients were assessed whether they fulfilled ex/inclusion criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:21 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Quasi-randomized by hospital number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:40 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:47 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>Open label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:26:55 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>Double-blind. The trace element solutions were transparent, colourless, and clinically undetectable, identified with a number code known to the pharmacist only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>Double-blind. All patients, pharmacists, medical- and nursing staff remained blinded throughout the trial period. In each centre, sequentially identical numbered boxes containing the whole treatment for each patient were delivered to the investigator by the pharmacist following the order of the randomizations list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-30 11:52:01 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-30 11:52:19 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>State blinded, no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>Single-blinded. Only patients were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Double-blind. The investigators were blinded to the study treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>Patients, clinicians and investigators were blinded to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-25 06:27:02 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-30 11:54:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Open-label trial </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-30 11:54:40 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-30 11:54:48 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-21 12:25:47 +0000" MODIFIED_BY="Jane Cracknell" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-11-30 11:54:48 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:50:06 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:50:16 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:51:03 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:51:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:52:02 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:52:20 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:52:31 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:52:44 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:53:05 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:53:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:02 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:22 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Data on inclusion and follow-up not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:40 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-30 11:54:48 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:50:07 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>None stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>249 randomized patients, 238 underwent ITT analysis. 14 patients failed exclusion/inclusion criteria after ITT analysis, 30 drug administration failure. 189 underwent per protocol analyse.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:51:24 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>All randomized patients were analysed according to the treatment group in which they were assigned </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:52:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>95 patients included. 15 lost to follow-up, 8 died within the first day after admission (lost to follow-up). 72 patients underwent per protocol analyse.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:26:57 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>No patients lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:52:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>No details on follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>All patients were followed up for the entire trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>No data on follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>States nothing on follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>105 patients were enrolled. Six patients were excluded from ITT analysis. Another 16 patients were excluded before protocol analysis. 83 patients were subjected to analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>1134 patients were screened for participation. 506 did not meet inclusion criteria. For 53 patients, trial parenteral nutrition was not immediately available, leaving 575 patients from whom consent was sought. 502 patients were randomized. No data on follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:54:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>286 patients enrolled, all subjected to ITT analysis. 42 patients were excluded. 244 were subjected to protocol-compatible analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-25 06:27:03 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:54:46 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>302 patients were enrolled in the trial, 2 patients were excluded before ITT-analysis. 300 patients were subjected to ITT analysis, 58 more patients were excluded from PC analysis. 242 patients were subjected to protocol-compatible analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-30 11:54:49 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>No data on follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-30 17:49:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 14:49:25 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>None. trial details available on <A HREF="http://ClinicalTrials.gov">ClinicalTrials.gov</A> (<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>Reports to have a follow-up period of 10 days. The average length of mechanical ventilation in the control group is set to 13 days (median) compared to 9 days (median) in the intervention group. The length of stay in hospital is stated as 17 days (median) for the control group and 12 days (median), longest range 20 days for the intervention group. It is unclear how long the patients have been followed-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:11 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-22 13:49:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>None. Full protocol and trial registration available (<LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on www.clinicaltrials.gov</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-20 13:00:12 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>Protocol or trial registration not available. Protocol not registered on <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="9">
<NAME>Funding bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:50:09 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>None stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:50:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>Sponsored by biosyn Arzneimittel GmbH, Fellbach, Germany </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:51:05 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:51:33 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>Funding by grant from the Ministry of Health, France</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-07-25 06:26:57 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>Financially supported by Slovak grant agency for Science</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:52:23 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:52:34 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:52:56 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>Supported in part by grant from the Comisión Sectorial para la Investigación Cient&#305;&#305;fica and the Fondo Clemente Estable 2004 and Ministerio de Educación y Cultura, Uruguay. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="YES" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Supported by National Health Service trust with a Research and Development grant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:53:48 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>None stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-07-25 06:27:01 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>Supported by Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-12-22 13:49:26 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>Funding was provided by Fresenius-Kabi and Oxford Nutrition as unrestricted grants for the trial nutrition components</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:54:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>Supported by Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:54:36 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:54:46 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-30 11:54:49 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Angstwurm-1999">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:50:52 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Angstwurm-2007">
<DESCRIPTION>
<P>The trial had two exclusion criteria which could lead to bias: primary concomitant disease with an expected high mortality within 2 months and patients with a "do-not-resuscitate code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:51:06 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Berger-2001">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:26:56 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Forceville-2007">
<DESCRIPTION>
<P>The principal Investigator, Xavier Forceville, is shareholder in a company named SE&#769;RE&#769;NITE&#769;-Forceville</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:15 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Janka-2013">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:26:58 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Kuklinski-1991">
<DESCRIPTION>
<P>Only men were included in the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:35 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Lindner-2004">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:52:58 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Manzanares-2011">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:26:59 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Mishra-2007">
<DESCRIPTION>
<P>Trial designed to recruit 80 patients to provide adequate power to analyse clinical endpoints, but ended the trial after recruiting only 40 patients due to an unexpectedly low consent rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-25 06:27:00 +0100" MODIFIED_BY="Mikkel Allingstrup" RESULT="NO" STUDY_ID="STD-Montoya-2009">
<DESCRIPTION>
<P>Does not describe the time from randomization to treatment initiation.</P>
<P>Does not describe how many patients randomized (error in flow-chart)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:10 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Ogawa-1999">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:32 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-SIGNET-2011">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:13 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Saito-1998">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:37 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Valenta-2011">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:47 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Yamaguchi-1998">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 11:54:50 +0000" MODIFIED_BY="Mikkel Allingstrup" RESULT="UNKNOWN" STUDY_ID="STD-Zimmermann-1997">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">Summary of findings table 1</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD COLSPAN="6">
<P>
<B>Selenium supplementation compared with control for critically ill adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>Patients with critical illnesses</P>
<P>
<B>Settings: </B>ICU setting</P>
<P>
<B>Intervention: </B>Selenium or ebselen</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Control</P>
</TH>
<TH VALIGN="TOP">
<P>Selenium</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Overall mortality (regardless of the follow-up period)</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>All patients are high risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.82</B>, 95% CI 0.72 to 0.93)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1391<BR/>(13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ICU length of stay (selenium)</B>
</P>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of stay in an ICU ranged across control groups from<BR/>9 days to 26.5 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of stay in an ICU ranged across intervention groups from<BR/>7.5 days to 22.8 days</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MD 0.54, 95% CI -2.27 to 3.34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>934<BR/>(7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Days on ventilator (selenium)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean days on ventilator ranged across control groups from</P>
<P>6 days to 16 days<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean days on ventilator ranged across intervention groups from<BR/>6 days to 19.8 days</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MD -0.86, 95% CI -4.39 to 2.67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,4</SUP>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Length of hospital stay (selenium)</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay ranged across control groups from<BR/>17 days to 62.8 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean length of hospital stay ranged across intervention groups from<BR/>12.5 days to 83 days<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MD -3.33. 95% CI -5.22 to -1.44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>693<BR/>(5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: CI: confidence interval; RR: risk ratio; MD: mean difference; ICU: intensive care unit.<BR/>
<SUP>1</SUP>With the exception of <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>, all included trials were at high risk of bias. Most studies were small and poorly described.<BR/>
<SUP>2</SUP>The entry refers to: <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Janka-2013" TYPE="STUDY">Janka 2013</LINK>; <LINK REF="STD-Kuklinski-1991" TYPE="STUDY">Kuklinski 1991</LINK>; <LINK REF="STD-Lindner-2004" TYPE="STUDY">Lindner 2004</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>; <LINK REF="STD-Valenta-2011" TYPE="STUDY">Valenta 2011</LINK>; and <LINK REF="STD-Zimmermann-1997" TYPE="STUDY">Zimmermann 1997</LINK>.<BR/>
<SUP>3</SUP>The entry refers to: <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>; <LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>; and <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>.<BR/>
<SUP>4</SUP>The entry refers to: <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; and <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>.<BR/>
<SUP>5</SUP>The entry refers to: <LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>; <LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>; <LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>; <LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>; and <LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-07-25 14:58:13 +0100" MODIFIED_BY="Mikkel Allingstrup">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-07-25 14:58:13 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1">
<TITLE MODIFIED="2015-07-25 14:58:13 +0100" MODIFIED_BY="Mikkel Allingstrup">Length of stay in ICU</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Selenium</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>
</P>
</TD>
<TD>
<P>22.8 days (20.8)</P>
</TD>
<TD>
<P>26.5 days (22)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Angstwurm-2007" TYPE="STUDY">Angstwurm 2007</LINK>
</P>
</TD>
<TD>
<P>15.1 days (10)</P>
</TD>
<TD>
<P>12.7 days (9)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>
</P>
</TD>
<TD>
<P>7,5 days (3.5)</P>
</TD>
<TD>
<P>9 days (7.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>
</P>
</TD>
<TD>
<P>22.3 days (9.6)</P>
</TD>
<TD>
<P>17 days (8.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Manzanares-2011" TYPE="STUDY">Manzanares 2011</LINK>
</P>
</TD>
<TD>
<P>14 days (11)</P>
</TD>
<TD>
<P>13days (6)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mishra-2007" TYPE="STUDY">Mishra 2007</LINK>
</P>
</TD>
<TD>
<P>21.3 days (16.2)</P>
</TD>
<TD>
<P>20.8 days (21.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>
</P>
</TD>
<TD>
<P>14.5 days (4.6)</P>
</TD>
<TD>
<P>16.7 days (5.9)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>MD 0.54 (95% CI -2.27 to 3.34, I² statistic = 72%, random-effects model)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>
</P>
<P>All findings given as mean (SD). If the original figures were provided in median (range) or interquartile range, we converted them to mean (SD) (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-07-25 13:22:29 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2">
<TITLE MODIFIED="2015-01-21 09:52:29 +0000" MODIFIED_BY="Mikkel Allingstrup">Number of days on a ventilator</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Selenium</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>
</P>
</TD>
<TD>
<P>11 days (5.9)</P>
</TD>
<TD>
<P>16 (12.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>
</P>
</TD>
<TD>
<P>6 days (2.9)</P>
</TD>
<TD>
<P>6 days (5.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>
</P>
</TD>
<TD>
<P>19.8 days (7.8)</P>
</TD>
<TD>
<P>14.8 days (4.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>
</P>
</TD>
<TD>
<P>9.3 days (1.5)</P>
</TD>
<TD>
<P>12 days (1.8)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>MD -0.86 (95% CI -4.39 to 2.67, I² statistic = 89%, random-effects model)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>)</P>
<P>All findings given as mean (SD). If the original figures were provided in median (range), we converted them to mean (SD) (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-07-25 13:22:46 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="3">
<TITLE MODIFIED="2015-01-21 10:08:25 +0000" MODIFIED_BY="Mikkel Allingstrup">Length of hospital stay</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Selenium</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Angstwurm-1999" TYPE="STUDY">Angstwurm 1999</LINK>
</P>
</TD>
<TD>
<P>38.5 days (24.4)</P>
</TD>
<TD>
<P>39.5 days (15.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berger-2001" TYPE="STUDY">Berger 2001</LINK>
</P>
</TD>
<TD>
<P>83 days (73.5)</P>
</TD>
<TD>
<P>62.8 days (30.2)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Forceville-2007" TYPE="STUDY">Forceville 2007</LINK>
</P>
</TD>
<TD>
<P>31.3 days (18)</P>
</TD>
<TD>
<P>32 days (11.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Montoya-2009" TYPE="STUDY">Montoya 2009</LINK>
</P>
</TD>
<TD>
<P>12.5 days (0.6)</P>
</TD>
<TD>
<P>17 days (1.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SIGNET-2011" TYPE="STUDY">SIGNET 2011</LINK>
</P>
</TD>
<TD>
<P>31.7 days (10.9)</P>
</TD>
<TD>
<P>33.8 days (12.4)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>MD -3.33 (95% CI -5.22 to -1.44, I² statistic = 42%, random-effects model)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>
</P>
<P>All findings given as mean (SD). If the original figures were provided in median (range) or interquartile range, we converted them to mean (SD) (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-07-25 14:51:31 +0100" MODIFIED_BY="Mikkel Allingstrup">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-30 21:36:36 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Selenium versus no selenium</NAME>
<DICH_OUTCOME CHI2="12.537623661565416" CI_END="0.9280565466637117" CI_START="0.7240997126694266" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8197594029836889" ESTIMABLE="YES" EVENTS_1="274" EVENTS_2="338" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.03242556132871774" LOG_CI_START="-0.1402016248521332" LOG_EFFECT_SIZE="-0.08631359309042547" METHOD="MH" MODIFIED="2015-01-30 21:36:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.637963671729841" P_Q="0.9450669548337728" P_Z="0.001693430101220998" Q="0.004747601900792591" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1037" TOTAL_2="1047" WEIGHT="100.00000000000003" Z="3.139315508526157">
<NAME>Overall mortality (regardless of the period of follow-up)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.628984213586797" CI_END="0.9293304332606436" CI_START="0.7205666325210064" DF="12" EFFECT_SIZE="0.8183180926717372" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="304" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.03182984055287082" LOG_CI_START="-0.1423258527429027" LOG_EFFECT_SIZE="-0.08707784664788674" MODIFIED="2015-01-30 21:36:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5609535164759287" P_Z="0.002007292665004753" STUDIES="13" TAU2="0.0" TOTAL_1="692" TOTAL_2="699" WEIGHT="89.90629285679769" Z="3.089151181087718">
<NAME>Overall mortality (Selenium)</NAME>
<DICH_DATA CI_END="1.319827561031643" CI_START="0.3068269595532726" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.12051719318732582" LOG_CI_START="-0.5131064834752623" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-10-28 10:51:57 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="168" O_E="0.0" SE="0.37219368415938836" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.13852813852813853" WEIGHT="3.2688539515879365"/>
<DICH_DATA CI_END="1.0241739190273411" CI_START="0.5735958362963378" EFFECT_SIZE="0.7664606288632088" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="61" LOG_CI_END="0.010373712167457414" LOG_CI_START="-0.24139400985086967" LOG_EFFECT_SIZE="-0.11551014884170616" MODIFIED="2014-10-28 10:51:57 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="169" O_E="0.0" SE="0.14788960618388894" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="122" TOTAL_2="124" VAR="0.021871335617225762" WEIGHT="17.979904735933054"/>
<DICH_DATA CI_END="25.035678251613096" CI_START="0.2840390837285556" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3985593615405136" LOG_CI_START="-0.5466218969959514" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2014-10-28 10:51:59 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="170" O_E="0.0" SE="1.1426091000668408" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" VAR="1.3055555555555556" WEIGHT="0.25471589233152747"/>
<DICH_DATA CI_END="1.2572505964263048" CI_START="0.6313528709455382" EFFECT_SIZE="0.890937019969278" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.09942185031769454" LOG_CI_START="-0.1997278403282039" LOG_EFFECT_SIZE="-0.050152995005254684" MODIFIED="2014-10-28 10:52:00 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="171" O_E="0.0" SE="0.17572200910025168" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" VAR="0.030878224482228933" WEIGHT="6.448557340859837"/>
<DICH_DATA CI_END="1.1486065719265612" CI_START="0.45230690630274184" EFFECT_SIZE="0.7207792207792207" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.06017129683394775" LOG_CI_START="-0.3445667809335591" LOG_EFFECT_SIZE="-0.14219774204980565" MODIFIED="2014-10-28 10:52:01 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="172" O_E="0.0" SE="0.23774515036643024" STUDY_ID="STD-Janka-2013" TOTAL_1="35" TOTAL_2="37" VAR="0.056522756522756526" WEIGHT="6.356104905865432"/>
<DICH_DATA CI_END="0.978645163321637" CI_START="0.004365076751053879" EFFECT_SIZE="0.06535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.009374745934777974" LOG_CI_START="-2.3600081157004196" LOG_EFFECT_SIZE="-1.1846914308175989" MODIFIED="2014-10-28 10:52:02 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="173" O_E="0.0" SE="1.3807736772231785" STUDY_ID="STD-Kuklinski-1991" TOTAL_1="8" TOTAL_2="9" VAR="1.9065359477124182" WEIGHT="2.392988777956719"/>
<DICH_DATA CI_END="6.445158746541576" CI_START="0.43098671219980617" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.809233618647991" LOG_CI_START="-0.3655361194152783" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-10-28 10:52:05 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="174" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Lindner-2004" TOTAL_1="35" TOTAL_2="35" VAR="0.47619047619047616" WEIGHT="0.8915056231603462"/>
<DICH_DATA CI_END="1.2343445305698901" CI_START="0.40967412243663426" EFFECT_SIZE="0.7111111111111111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.09143639700787289" LOG_CI_START="-0.3875614679187483" LOG_EFFECT_SIZE="-0.14806253545543768" MODIFIED="2014-10-28 10:52:06 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="175" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Manzanares-2011" TOTAL_1="15" TOTAL_2="16" VAR="0.07916666666666666" WEIGHT="3.450989509007792"/>
<DICH_DATA CI_END="1.727337361017546" CI_START="0.4574227794880062" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.23737716658876326" LOG_CI_START="-0.33968221148352584" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-10-28 10:52:07 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="176" O_E="0.0" SE="0.33896753516965294" STUDY_ID="STD-Mishra-2007" TOTAL_1="18" TOTAL_2="22" VAR="0.1148989898989899" WEIGHT="2.941968556429143"/>
<DICH_DATA CI_END="1.9310723434935433" CI_START="0.2912889317146812" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2857985439976904" LOG_CI_START="-0.5356760172142903" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-10-28 10:52:09 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="177" O_E="0.0" SE="0.4825382236205769" STUDY_ID="STD-Montoya-2009" TOTAL_1="34" TOTAL_2="34" VAR="0.2328431372549019" WEIGHT="2.37734832842759"/>
<DICH_DATA CI_END="1.143492714623724" CI_START="0.7704145046831657" EFFECT_SIZE="0.9385964912280702" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="114" LOG_CI_END="0.058233401991482255" LOG_CI_START="-0.11327554929400814" LOG_EFFECT_SIZE="-0.02752107365126294" MODIFIED="2014-10-28 10:52:04 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="178" O_E="0.0" SE="0.10074520696809813" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.010149596727044928" WEIGHT="33.877213680093156"/>
<DICH_DATA CI_END="1.2833387233094264" CI_START="0.44725740105759876" EFFECT_SIZE="0.7576164874551972" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.10834129881374144" LOG_CI_START="-0.3494424641493402" LOG_EFFECT_SIZE="-0.12055058266779937" MODIFIED="2014-10-28 10:52:10 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="179" O_E="0.0" SE="0.2689044484306875" STUDY_ID="STD-Valenta-2011" TOTAL_1="93" TOTAL_2="89" VAR="0.07230960238581229" WEIGHT="7.288793226717557"/>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2014-10-28 10:52:12 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="180" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Zimmermann-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="2.37734832842759"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.924381140587538" CI_END="1.3392966381142117" CI_START="0.5175988588013731" DF="2" EFFECT_SIZE="0.8325973885885252" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.12687677867602018" LOG_CI_START="-0.28600668986797423" LOG_EFFECT_SIZE="-0.07956495559597702" MODIFIED="2015-01-30 21:36:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38205512861357127" P_Z="0.45001378065988984" STUDIES="3" TAU2="0.0" TOTAL_1="345" TOTAL_2="348" WEIGHT="10.093707143202332" Z="0.7553920623151669">
<NAME>Overall mortality (Ebselen)</NAME>
<DICH_DATA CI_END="5.946459187109174" CI_START="0.533569888006321" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.774258442495517" LOG_CI_START="-0.272808687790346" LOG_EFFECT_SIZE="0.2507248773525854" MODIFIED="2014-10-28 10:52:13 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="181" O_E="0.0" SE="0.6150524153958022" STUDY_ID="STD-Ogawa-1999" TOTAL_1="48" TOTAL_2="57" VAR="0.3782894736842105" WEIGHT="1.086787807281184"/>
<DICH_DATA CI_END="1.6027349183752175" CI_START="0.3775900103461379" EFFECT_SIZE="0.7779310344827586" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.20486169889394573" LOG_CI_START="-0.4229795040692486" LOG_EFFECT_SIZE="-0.10905890258765143" MODIFIED="2014-10-28 10:52:15 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="182" O_E="0.0" SE="0.368797030484658" STUDY_ID="STD-Saito-1998" TOTAL_1="145" TOTAL_2="141" VAR="0.13601124969430178" WEIGHT="4.519871166372385"/>
<DICH_DATA CI_END="1.4176321071605322" CI_START="0.305315802723654" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.15156354074835293" LOG_CI_START="-0.515250716637898" LOG_EFFECT_SIZE="-0.1818435879447725" MODIFIED="2014-10-28 10:52:16 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="183" O_E="0.0" SE="0.39168999557249223" STUDY_ID="STD-Yamaguchi-1998" TOTAL_1="152" TOTAL_2="150" VAR="0.15342105263157899" WEIGHT="4.487048169548763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-01-30 21:37:12 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Selenium versus no selenium</NAME>
<DICH_OUTCOME CHI2="12.731914211056008" CI_END="1.0323682336687996" CI_START="0.7777191141704716" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8960426932834358" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="339" I2="13.60293654470328" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.013834632684499363" LOG_CI_START="-0.1091772271645217" LOG_EFFECT_SIZE="-0.04767129724001113" METHOD="MH" MODIFIED="2015-01-30 21:36:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3112080591454278" P_Q="0.36287639013846906" P_Z="0.1287358228317778" Q="0.8279143042935904" RANDOM="YES" SCALE="30.0" SORT_BY="EFFECT_SIZE" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008696286556912132" TOTALS="SUB" TOTAL_1="894" TOTAL_2="900" WEIGHT="200.0" Z="1.5191059756579903">
<NAME>Mortality by duration (Selenium)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.161581307856213" CI_END="1.0238998746024182" CI_START="0.690644221014423" DF="8" EFFECT_SIZE="0.8409224288194199" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="224" I2="21.27209577297809" ID="CMP-002.01.01" LOG_CI_END="0.010257489810020039" LOG_CI_START="-0.1607456178086009" LOG_EFFECT_SIZE="-0.07524406399929046" MODIFIED="2014-10-23 21:50:59 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.25386784462580425" P_Z="0.08455809158892828" STUDIES="9" TAU2="0.01792232119343031" TOTAL_1="587" TOTAL_2="593" WEIGHT="100.0" Z="1.7248301220109195">
<NAME>Selenium 28 day</NAME>
<DICH_DATA CI_END="0.978645163321637" CI_START="0.004365076751053879" EFFECT_SIZE="0.06535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.009374745934777974" LOG_CI_START="-2.3600081157004196" LOG_EFFECT_SIZE="-1.1846914308175989" ORDER="830" O_E="0.0" SE="1.3807736772231785" STUDY_ID="STD-Kuklinski-1991" TOTAL_1="8" TOTAL_2="9" VAR="1.9065359477124182" WEIGHT="0.524293787518783"/>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="832" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Zimmermann-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="2.6816381430746508"/>
<DICH_DATA CI_END="1.1486065719265612" CI_START="0.45230690630274184" EFFECT_SIZE="0.7207792207792207" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.06017129683394775" LOG_CI_START="-0.3445667809335591" LOG_EFFECT_SIZE="-0.14219774204980565" MODIFIED="2014-10-23 21:50:59 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="48" O_E="0.0" SE="0.23774515036643024" STUDY_ID="STD-Janka-2013" TOTAL_1="35" TOTAL_2="37" VAR="0.056522756522756526" WEIGHT="13.55336774008232"/>
<DICH_DATA CI_END="1.2833387233094264" CI_START="0.44725740105759876" EFFECT_SIZE="0.7576164874551972" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.10834129881374144" LOG_CI_START="-0.3494424641493402" LOG_EFFECT_SIZE="-0.12055058266779937" MODIFIED="2011-04-21 15:52:33 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.2689044484306875" STUDY_ID="STD-Valenta-2011" TOTAL_1="93" TOTAL_2="89" VAR="0.07230960238581229" WEIGHT="11.182090270306496"/>
<DICH_DATA CI_END="1.0241739190273411" CI_START="0.5735958362963378" EFFECT_SIZE="0.7664606288632088" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="61" LOG_CI_END="0.010373712167457414" LOG_CI_START="-0.24139400985086967" LOG_EFFECT_SIZE="-0.11551014884170616" ORDER="828" O_E="0.0" SE="0.14788960618388894" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="122" TOTAL_2="124" VAR="0.021871335617225762" WEIGHT="25.35533538743038"/>
<DICH_DATA CI_END="1.727337361017546" CI_START="0.4574227794880062" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.23737716658876326" LOG_CI_START="-0.33968221148352584" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="831" O_E="0.0" SE="0.33896753516965294" STUDY_ID="STD-Mishra-2007" TOTAL_1="18" TOTAL_2="22" VAR="0.1148989898989899" WEIGHT="7.59653331553409"/>
<DICH_DATA CI_END="1.763554605307128" CI_START="0.575510250753123" EFFECT_SIZE="1.0074441687344913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.24638891136184224" LOG_CI_START="-0.23994693648967294" LOG_EFFECT_SIZE="0.003220987436084647" MODIFIED="2011-04-15 14:38:38 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.28567608442925296" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" VAR="0.08161082521482967" WEIGHT="10.13714075296986"/>
<DICH_DATA CI_END="1.3506130799414349" CI_START="0.8000111624959665" EFFECT_SIZE="1.0394736842105263" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="76" LOG_CI_END="0.13053095130662934" LOG_CI_START="-0.09690395328732918" LOG_EFFECT_SIZE="0.016813499009650082" MODIFIED="2011-04-27 16:50:15 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.13359638877942595" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.017847995094903528" WEIGHT="28.207229329296084"/>
<DICH_DATA CI_END="25.035678251613096" CI_START="0.2840390837285556" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3985593615405136" LOG_CI_START="-0.5466218969959514" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="829" O_E="0.0" SE="1.1426091000668408" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" VAR="1.3055555555555556" WEIGHT="0.7623712737873395"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8990295926311478" CI_END="1.176092099126896" CI_START="0.7822668328209529" DF="2" EFFECT_SIZE="0.9591756051369025" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="115" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.07044133243437295" LOG_CI_START="-0.10664508293076043" LOG_EFFECT_SIZE="-0.018101875248193743" MODIFIED="2014-09-08 16:56:51 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.3869287866219747" P_Z="0.6886430058041879" STUDIES="3" TAU2="0.0" TOTAL_1="307" TOTAL_2="307" WEIGHT="100.0" Z="0.4006972919514218">
<NAME>Selenium 90 day</NAME>
<DICH_DATA CI_END="1.319827561031643" CI_START="0.3068269595532726" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.12051719318732582" LOG_CI_START="-0.5131064834752623" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="833" O_E="0.0" SE="0.37219368415938836" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.13852813852813853" WEIGHT="7.81101909388586"/>
<DICH_DATA CI_END="1.2153175993474223" CI_START="0.7905654937767942" EFFECT_SIZE="0.9801980198019802" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="101" LOG_CI_END="0.08468978708627378" LOG_CI_START="-0.10206214545645914" LOG_EFFECT_SIZE="-0.008686179185092667" MODIFIED="2014-09-08 16:56:51 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="41" O_E="0.0" SE="0.10969900961257655" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.012033872709980162" WEIGHT="89.91668444243825"/>
<DICH_DATA CI_END="6.445158746541576" CI_START="0.43098671219980617" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.809233618647991" LOG_CI_START="-0.3655361194152783" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="834" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Lindner-2004" TOTAL_1="35" TOTAL_2="35" VAR="0.47619047619047616" WEIGHT="2.2722964636758864"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.924381140587538" CI_END="1.3466960516434887" CI_START="0.5132658188310592" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8313922369515785" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" I2_Q="45.27455199250375" ID="CMP-002.02" LOG_CI_END="0.12926958682216988" LOG_CI_START="-0.28965765681334515" LOG_EFFECT_SIZE="-0.08019403499558761" METHOD="MH" MODIFIED="2015-01-30 21:37:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38205512861357127" P_Q="0.17644654496191126" P_Z="0.45302556898932067" Q="1.8273034509704167" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="345" TOTAL_2="348" WEIGHT="200.0" Z="0.7503805147752466">
<NAME>Mortality by duration (Ebselen)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.946459187109174" CI_START="0.533569888006321" DF="0" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.774258442495517" LOG_CI_START="-0.272808687790346" LOG_EFFECT_SIZE="0.2507248773525854" NO="1" P_CHI2="1.0" P_Z="0.34791347714447496" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="57" WEIGHT="100.0" Z="0.9386441717545425">
<NAME>Ebselen 30 day</NAME>
<DICH_DATA CI_END="5.946459187109174" CI_START="0.533569888006321" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.774258442495517" LOG_CI_START="-0.272808687790346" LOG_EFFECT_SIZE="0.2507248773525854" ORDER="842" O_E="0.0" SE="0.6150524153958022" STUDY_ID="STD-Ogawa-1999" TOTAL_1="48" TOTAL_2="57" VAR="0.3782894736842105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09706399283368586" CI_END="1.2170034107335272" CI_START="0.4247993329089069" DF="1" EFFECT_SIZE="0.7190147682958027" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.08529179537112863" LOG_CI_START="-0.3718161739280189" LOG_EFFECT_SIZE="-0.14326218927844514" NO="2" P_CHI2="0.7553818405910775" P_Z="0.21924267387381013" STUDIES="2" TAU2="0.0" TOTAL_1="297" TOTAL_2="291" WEIGHT="100.0" Z="1.2285444585996916">
<NAME>Ebselen 3 month</NAME>
<DICH_DATA CI_END="1.6027349183752175" CI_START="0.3775900103461379" EFFECT_SIZE="0.7779310344827586" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.20486169889394573" LOG_CI_START="-0.4229795040692486" LOG_EFFECT_SIZE="-0.10905890258765143" ORDER="843" O_E="0.0" SE="0.368797030484658" STUDY_ID="STD-Saito-1998" TOTAL_1="145" TOTAL_2="141" VAR="0.13601124969430178" WEIGHT="53.00757773015863"/>
<DICH_DATA CI_END="1.4176321071605322" CI_START="0.305315802723654" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.15156354074835293" LOG_CI_START="-0.515250716637898" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="844" O_E="0.0" SE="0.39168999557249223" STUDY_ID="STD-Yamaguchi-1998" TOTAL_1="152" TOTAL_2="150" VAR="0.15342105263157899" WEIGHT="46.99242226984136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.467115798226134" CI_END="1.0239588466185545" CI_START="0.739343299368029" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8700902896113965" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="267" I2="12.79411339382379" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.010282502493694369" LOG_CI_START="-0.13115385876129546" LOG_EFFECT_SIZE="-0.06043567813380052" METHOD="MH" MODIFIED="2015-01-30 21:37:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3223011257095004" P_Q="0.6490862037248273" P_Z="0.09393756111056423" Q="0.20705415375770977" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009425773604729504" TOTALS="YES" TOTAL_1="624" TOTAL_2="631" WEIGHT="100.00000000000001" Z="1.6749830308480882">
<NAME>Mortality: ICU and pancreatitis (Selenium)</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.820562481833196" CI_END="1.0092613429043373" CI_START="0.7719496647496539" DF="8" EFFECT_SIZE="0.8826658231175537" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="256" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.004003639066330432" LOG_CI_START="-0.11241101706602556" LOG_EFFECT_SIZE="-0.05420368899984758" MODIFIED="2014-09-08 17:11:49 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="1" P_CHI2="0.5561108989755367" P_Z="0.06797794711834741" STUDIES="9" TAU2="0.0" TOTAL_1="581" TOTAL_2="587" WEIGHT="98.21838440407045" Z="1.825152979846905">
<NAME>General intensive care patients</NAME>
<DICH_DATA CI_END="1.319827561031643" CI_START="0.3068269595532726" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.12051719318732582" LOG_CI_START="-0.5131064834752623" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="835" O_E="0.0" SE="0.37219368415938836" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.13852813852813853" WEIGHT="4.665206803657085"/>
<DICH_DATA CI_END="1.0241739190273411" CI_START="0.5735958362963378" EFFECT_SIZE="0.7664606288632088" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="61" LOG_CI_END="0.010373712167457414" LOG_CI_START="-0.24139400985086967" LOG_EFFECT_SIZE="-0.11551014884170616" ORDER="836" O_E="0.0" SE="0.14788960618388894" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="122" TOTAL_2="124" VAR="0.021871335617225762" WEIGHT="22.054292382560714"/>
<DICH_DATA CI_END="25.035678251613096" CI_START="0.2840390837285556" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3985593615405136" LOG_CI_START="-0.5466218969959514" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="837" O_E="0.0" SE="1.1426091000668408" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" VAR="1.3055555555555556" WEIGHT="0.5249014432400392"/>
<DICH_DATA CI_END="1.5325238739687976" CI_START="0.7656028105814917" EFFECT_SIZE="1.0831918505942275" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.18540724877097436" LOG_CI_START="-0.115996480902853" LOG_EFFECT_SIZE="0.03470538393406068" MODIFIED="2011-04-15 14:40:06 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.17704604278293032" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" VAR="0.03134530126509519" WEIGHT="16.929541340613337"/>
<DICH_DATA CI_END="2.1612453107597456" CI_START="0.33289486894797726" EFFECT_SIZE="0.8482142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3347040639970161" LOG_CI_START="-0.47769289875968374" LOG_EFFECT_SIZE="-0.07149441738133386" MODIFIED="2014-09-08 17:11:49 +0100" MODIFIED_BY="Mikkel Allingstrup" ORDER="38" O_E="0.0" SE="0.4772059973531079" STUDY_ID="STD-Manzanares-2011" TOTAL_1="16" TOTAL_2="19" VAR="0.22772556390977444" WEIGHT="2.910527955456816"/>
<DICH_DATA CI_END="1.727337361017546" CI_START="0.4574227794880062" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.23737716658876326" LOG_CI_START="-0.33968221148352584" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="838" O_E="0.0" SE="0.33896753516965294" STUDY_ID="STD-Mishra-2007" TOTAL_1="18" TOTAL_2="22" VAR="0.1148989898989899" WEIGHT="5.55187541128352"/>
<DICH_DATA CI_END="1.143492714623724" CI_START="0.7704145046831657" EFFECT_SIZE="0.9385964912280702" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="114" LOG_CI_END="0.058233401991482255" LOG_CI_START="-0.11327554929400814" LOG_EFFECT_SIZE="-0.02752107365126294" MODIFIED="2011-03-01 17:21:15 +0000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.10074520696809813" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.010149596727044928" WEIGHT="35.26041070035641"/>
<DICH_DATA CI_END="1.2833387233094264" CI_START="0.44725740105759876" EFFECT_SIZE="0.7576164874551972" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.10834129881374144" LOG_CI_START="-0.3494424641493402" LOG_EFFECT_SIZE="-0.12055058266779937" MODIFIED="2011-04-21 15:53:44 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.2689044484306875" STUDY_ID="STD-Valenta-2011" TOTAL_1="93" TOTAL_2="89" VAR="0.07230960238581229" WEIGHT="8.444759556618555"/>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="839" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Zimmermann-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="1.8768688102839735"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.215547824172665" CI_END="12.299619856569215" CI_START="0.012857461699645375" DF="1" EFFECT_SIZE="0.39767058129315574" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="80.82655871037615" ID="CMP-002.03.02" LOG_CI_END="1.0898916889397579" LOG_CI_START="-1.8908447606998486" LOG_EFFECT_SIZE="-0.4004765358800454" NO="2" P_CHI2="0.02238584072935501" P_Z="0.5984286677387642" STUDIES="2" TAU2="5.02224859594128" TOTAL_1="43" TOTAL_2="44" WEIGHT="1.7816155959295659" Z="0.5266615148569438">
<NAME>Acute pancreatitis</NAME>
<DICH_DATA CI_END="0.978645163321637" CI_START="0.004365076751053879" EFFECT_SIZE="0.06535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.009374745934777974" LOG_CI_START="-2.3600081157004196" LOG_EFFECT_SIZE="-1.1846914308175989" ORDER="840" O_E="0.0" SE="1.3807736772231785" STUDY_ID="STD-Kuklinski-1991" TOTAL_1="8" TOTAL_2="9" VAR="1.9065359477124182" WEIGHT="0.36025542150989787"/>
<DICH_DATA CI_END="6.445158746541576" CI_START="0.43098671219980617" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.809233618647991" LOG_CI_START="-0.3655361194152783" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="841" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Lindner-2004" TOTAL_1="35" TOTAL_2="35" VAR="0.47619047619047616" WEIGHT="1.421360174419668"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-23 15:58:23 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="3">
<NAME>Selenium versus no selenium</NAME>
<DICH_OUTCOME CHI2="12.483753509650304" CI_END="1.1046212172974295" CI_START="0.7053148366692542" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8826696627048701" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="243" I2="35.91670971542519" I2_Q="59.425360259176884" ID="CMP-003.01" LOG_CI_END="0.043213380791241957" LOG_CI_START="-0.1516169804460328" LOG_EFFECT_SIZE="-0.054201799827395425" METHOD="MH" MODIFIED="2011-10-14 15:25:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13088983868089998" P_Q="0.11643805621946657" P_Z="0.27548248035311285" Q="2.4645936634007275" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.046006485307106" TOTALS="SUB" TOTAL_1="803" TOTAL_2="816" WEIGHT="200.0" Z="1.0905238268235564">
<NAME>Number of infected participants</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.955222890404594" CI_END="1.2316311998031704" CI_START="0.749801557977076" DF="5" EFFECT_SIZE="0.9609781435941155" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="177" I2="16.04008629036715" ID="CMP-003.01.01" LOG_CI_END="0.09048068196120936" LOG_CI_START="-0.12505366151363576" LOG_EFFECT_SIZE="-0.017286489776213238" MODIFIED="2011-10-14 15:25:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31060060661852285" P_Z="0.753225018027935" STUDIES="6" TAU2="0.018983621565939482" TOTAL_1="464" TOTAL_2="470" WEIGHT="100.0" Z="0.31438977969143955">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="2.3546553613523216" CI_START="0.4387290162130695" EFFECT_SIZE="1.0163934426229508" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3719273506938094" LOG_CI_START="-0.3578036417188357" LOG_EFFECT_SIZE="0.007061854487486849" ORDER="845" O_E="0.0" SE="0.4286475971698574" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="122" TOTAL_2="124" VAR="0.18373876255949234" WEIGHT="7.906903907347338"/>
<DICH_DATA CI_END="3.242339542503021" CI_START="0.5483009273005901" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.510858492842532" LOG_CI_START="-0.2609810196259322" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="846" O_E="0.0" SE="0.4533823502911815" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" VAR="0.2055555555555556" WEIGHT="7.138649173372691"/>
<DICH_DATA CI_END="2.047121392843919" CI_START="0.7310383314998656" EFFECT_SIZE="1.2233250620347396" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.31114359678028247" LOG_CI_START="-0.13605985050804126" LOG_EFFECT_SIZE="0.08754187313612061" MODIFIED="2011-10-14 15:25:22 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.2626895186299274" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" VAR="0.06900578319802296" WEIGHT="18.21703892017511"/>
<DICH_DATA CI_END="100.52959945656309" CI_START="0.24868297630890304" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002293952184388" LOG_CI_START="-0.6043539435123508" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="847" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Lindner-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="0.6782124805067379"/>
<DICH_DATA CI_END="1.0762479573824362" CI_START="0.11792269767337837" EFFECT_SIZE="0.35625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03191234021234679" LOG_CI_START="-0.9284025941792134" LOG_EFFECT_SIZE="-0.4482451269834334" MODIFIED="2011-04-27 16:39:31 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.5640937460971934" STUDY_ID="STD-Manzanares-2011" TOTAL_1="16" TOTAL_2="19" VAR="0.31820175438596493" WEIGHT="4.753783898910198"/>
<DICH_DATA CI_END="1.0700273623155574" CI_START="0.7679211097711773" EFFECT_SIZE="0.9064748201438849" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="139" LOG_CI_END="0.029394883433545925" LOG_CI_START="-0.11468339370661026" LOG_EFFECT_SIZE="-0.042644255136532166" MODIFIED="2011-03-04 14:43:25 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.08463229319110195" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.007162625050784643" WEIGHT="61.305411619687916"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.989920428502227" CI_END="1.0201353616217845" CI_START="0.35733984880052494" DF="2" EFFECT_SIZE="0.6037673524446294" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="66" I2="33.10858774252125" ID="CMP-003.01.02" LOG_CI_END="0.0086578020609601" LOG_CI_START="-0.44691855069037906" LOG_EFFECT_SIZE="-0.21913037431470947" NO="2" P_CHI2="0.2242575926506123" P_Z="0.059366488831821954" STUDIES="3" TAU2="0.07545078584851021" TOTAL_1="339" TOTAL_2="346" WEIGHT="100.0" Z="1.8854694234317855">
<NAME>Ebselen</NAME>
<DICH_DATA CI_END="5.260386812565539" CI_START="0.012761057611429668" EFFECT_SIZE="0.2590909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7210176803488264" LOG_CI_START="-1.894113330648256" LOG_EFFECT_SIZE="-0.5865478251497148" ORDER="848" O_E="0.0" SE="1.5361409009669666" STUDY_ID="STD-Ogawa-1999" TOTAL_1="43" TOTAL_2="56" VAR="2.359728867623604" WEIGHT="2.94080714162392"/>
<DICH_DATA CI_END="1.1999467893956117" CI_START="0.524440746878169" EFFECT_SIZE="0.7932849364791289" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" LOG_CI_END="0.07916198806076406" LOG_CI_START="-0.28030357278502893" LOG_EFFECT_SIZE="-0.10057079236213244" ORDER="849" O_E="0.0" SE="0.2111518498240426" STUDY_ID="STD-Saito-1998" TOTAL_1="145" TOTAL_2="141" VAR="0.04458510368411503" WEIGHT="59.66043775700617"/>
<DICH_DATA CI_END="0.8139229954677135" CI_START="0.21412826495357606" EFFECT_SIZE="0.4174732552215996" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="26" LOG_CI_END="-0.08941668138278044" LOG_CI_START="-0.6693260020041961" LOG_EFFECT_SIZE="-0.3793713416934883" ORDER="850" O_E="0.0" SE="0.3406416055304531" STUDY_ID="STD-Yamaguchi-1998" TOTAL_1="151" TOTAL_2="149" VAR="0.11603670341836482" WEIGHT="37.3987551013699"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-07-25 14:51:31 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="4">
<NAME>Selenium versus no selenium</NAME>
<DICH_OUTCOME CHI2="11.85635700316973" CI_END="1.241928384843057" CI_START="0.853527415870732" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0295726904942681" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="210" I2="40.959942433172436" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.09409655319627307" LOG_CI_START="-0.06878252449634767" LOG_EFFECT_SIZE="0.012657014349962645" METHOD="MH" MODIFIED="2011-10-21 14:44:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1053827442344828" P_Q="0.8204383231796364" P_Z="0.760663256151333" Q="0.051520487942046736" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.024211108332199586" TOTALS="SUB" TOTAL_1="756" TOTAL_2="757" WEIGHT="200.0" Z="0.30460993062041886">
<NAME>Number of participants with adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.526448047698748" CI_END="1.2408116612318119" CI_START="0.847656305134074" DF="5" EFFECT_SIZE="1.0255641511514675" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="185" I2="41.35893431791356" ID="CMP-004.01.01" LOG_CI_END="0.09370586635360638" LOG_CI_START="-0.07178020321552112" LOG_EFFECT_SIZE="0.010962831569042653" MODIFIED="2011-10-21 14:44:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12950990633931914" P_Z="0.7951102133955457" STUDIES="6" TAU2="0.019948447967042426" TOTAL_1="459" TOTAL_2="466" WEIGHT="99.99999999999999" Z="0.25968052899977573">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="1.061414694141651" CI_START="0.10468209242285352" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.025885095673677673" LOG_CI_START="-0.9801276051130026" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="851" O_E="0.0" SE="0.5909368402852788" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.3492063492063492" WEIGHT="2.5597029563145313"/>
<DICH_DATA CI_END="1.0064614710244693" CI_START="0.8770371755066192" EFFECT_SIZE="0.939523350323736" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="119" LOG_CI_END="0.0027971540465869076" LOG_CI_START="-0.056981997540224705" LOG_EFFECT_SIZE="-0.027092421746818893" ORDER="852" O_E="0.0" SE="0.03511456955366588" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="122" TOTAL_2="124" VAR="0.0012330329949392389" WEIGHT="44.61098009900521"/>
<DICH_DATA CI_END="1.8121512460406843" CI_START="0.931565021558338" EFFECT_SIZE="1.299283154121864" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.2581944420050788" LOG_CI_START="-0.03078682673824884" LOG_EFFECT_SIZE="0.11370380763341498" MODIFIED="2011-04-15 14:43:09 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.1697490277401814" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" VAR="0.028814732418736874" WEIGHT="19.377871135287734"/>
<DICH_DATA CI_END="1.4916243893488137" CI_START="0.823533582951169" EFFECT_SIZE="1.1083333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.17365947583770822" LOG_CI_START="-0.0843186859987862" LOG_EFFECT_SIZE="0.04467039491946099" MODIFIED="2011-10-14 12:07:43 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.15153764927525332" STUDY_ID="STD-Manzanares-2011" TOTAL_1="16" TOTAL_2="19" VAR="0.022963659147869686" WEIGHT="22.020047235901316"/>
<DICH_DATA CI_END="2.288893465351115" CI_START="0.33298042310621595" EFFECT_SIZE="0.873015873015873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.359625579268311" LOG_CI_START="-0.47758129918698666" LOG_EFFECT_SIZE="-0.05897785995933786" ORDER="853" O_E="0.0" SE="0.4917794646455277" STUDY_ID="STD-Mishra-2007" TOTAL_1="18" TOTAL_2="22" VAR="0.2418470418470418" WEIGHT="3.609407581213364"/>
<DICH_DATA CI_END="2.1923174623884463" CI_START="0.6313333122269589" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.34090344314290705" LOG_CI_START="-0.19974129457149248" LOG_EFFECT_SIZE="0.07058107428570728" MODIFIED="2011-10-21 14:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.3175773951680517" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" VAR="0.10085540192172487" WEIGHT="7.8219909922778355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.147030414917035" CI_END="3.355731105428543" CI_START="0.40228634971010413" DF="1" EFFECT_SIZE="1.1618798634159648" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="68.22401222244422" ID="CMP-004.01.02" LOG_CI_END="0.5257871535549828" LOG_CI_START="-0.3954647035613635" LOG_EFFECT_SIZE="0.06516122499680967" NO="2" P_CHI2="0.07606559338815744" P_Z="0.7815796228424493" STUDIES="2" TAU2="0.408302269663702" TOTAL_1="297" TOTAL_2="291" WEIGHT="100.0" Z="0.2772611055179211">
<NAME>Ebselen</NAME>
<DICH_DATA CI_END="1.3666781358299562" CI_START="0.3891871576254671" EFFECT_SIZE="0.7293103448275862" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.13566624661477675" LOG_CI_START="-0.40984149899056666" LOG_EFFECT_SIZE="-0.13708762618789497" ORDER="854" O_E="0.0" SE="0.3204339500754695" STUDY_ID="STD-Saito-1998" TOTAL_1="145" TOTAL_2="141" VAR="0.10267791636096846" WEIGHT="57.30966853859607"/>
<DICH_DATA CI_END="6.0981857130954555" CI_START="0.7729298107409234" EFFECT_SIZE="2.1710526315789473" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7852006461599698" LOG_CI_START="-0.11185994229373984" LOG_EFFECT_SIZE="0.33667035193311495" ORDER="855" O_E="0.0" SE="0.5269378301792377" STUDY_ID="STD-Yamaguchi-1998" TOTAL_1="152" TOTAL_2="150" VAR="0.27766347687400317" WEIGHT="42.69033146140392"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="21.14132620108692" CI_END="3.3415506435013094" CI_START="-2.2657534958623784" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5378985738194654" ESTIMABLE="YES" I2="71.6195666112397" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2015-07-25 14:51:31 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" P_CHI2="0.0017303673314741363" P_Q="1.0" P_Z="0.7068933890590696" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="7.58428257504475" TOTALS="YES" TOTAL_1="461" TOTAL_2="473" UNITS="" WEIGHT="100.0" Z="0.3760316208356227">
<NAME>Length of stay in ICU (Selenium)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.016411588580004" CI_START="-16.416411588580004" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" MEAN_1="22.8" MEAN_2="26.5" MODIFIED="2014-11-16 20:33:18 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="103" SD_1="20.0" SD_2="22.0" SE="6.488084316286133" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="4.118837473384226"/>
<CONT_DATA CI_END="-1.2744734454569415" CI_START="-3.125526554543057" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="16.7" MODIFIED="2014-11-15 17:49:30 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="46" SD_1="4.6" SD_2="5.9" SE="0.4722161028689777" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" WEIGHT="26.209142897846554"/>
<CONT_DATA CI_END="3.1223349669103166" CI_START="-6.122334966910317" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.0" MODIFIED="2014-11-15 17:49:30 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="65" SD_1="3.5" SD_2="7.1" SE="2.3583775025310185" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" WEIGHT="15.565064492890368"/>
<CONT_DATA CI_END="12.289442930151388" CI_START="-11.289442930151388" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="21.3" MEAN_2="20.8" MODIFIED="2014-11-15 17:49:31 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="70" SD_1="16.2" SD_2="21.8" SE="6.0151324326084605" STUDY_ID="STD-Mishra-2007" TOTAL_1="18" TOTAL_2="22" WEIGHT="4.675350736253118"/>
<CONT_DATA CI_END="7.295319703305602" CI_START="-5.295319703305602" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="13.0" MODIFIED="2014-11-15 17:49:31 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="69" SD_1="11.0" SD_2="6.0" SE="3.2119568282694377" STUDY_ID="STD-Manzanares-2011" TOTAL_1="15" TOTAL_2="16" WEIGHT="11.430783286046815"/>
<CONT_DATA CI_END="4.82117310195589" CI_START="-0.021173101955889173" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" MEAN_1="15.1" MEAN_2="12.7" MODIFIED="2014-11-15 17:51:52 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="65" SD_1="10.0" SD_2="9.0" SE="1.2353150981619019" STUDY_ID="STD-Angstwurm-2007" TOTAL_1="116" TOTAL_2="122" WEIGHT="22.460532209681215"/>
<CONT_DATA CI_END="9.931035828176661" CI_START="0.6689641718233412" EFFECT_SIZE="5.300000000000001" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="17.0" MODIFIED="2014-11-16 20:33:22 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="47" SD_1="9.6" SD_2="8.7" SE="2.362816799035941" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" WEIGHT="15.540288903897698"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.68544202275987" CI_END="2.67215627480268" CI_START="-4.386682111226969" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.857262918212145" ESTIMABLE="YES" I2="88.75791528039402" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2015-01-21 14:31:33 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="3" P_CHI2="6.852600696771738E-6" P_Q="1.0" P_Z="0.6340338258465187" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="11.038495122754883" TOTALS="YES" TOTAL_1="95" TOTAL_2="96" UNITS="" WEIGHT="100.0" Z="0.4760569241258877">
<NAME>Number of days on a ventilator (Selenium)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.361751048540578" CI_START="-7.638248951459422" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="16.0" MODIFIED="2014-11-15 18:02:56 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="66" SD_1="5.9" SD_2="1.8" SE="1.346070117751955" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="25.234439434286156"/>
<CONT_DATA CI_END="-1.912419772049132" CI_START="-3.4875802279508665" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="12.0" MODIFIED="2014-11-15 18:03:29 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="69" SD_1="1.5" SD_2="1.8" SE="0.40183403070831886" STUDY_ID="STD-Montoya-2009" TOTAL_1="34" TOTAL_2="34" WEIGHT="28.953002711213927"/>
<CONT_DATA CI_END="3.740371587234226" CI_START="-3.740371587234226" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" MODIFIED="2014-11-15 18:00:57 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="67" SD_1="2.9" SD_2="5.7" SE="1.908387917705529" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" WEIGHT="22.088755320401145"/>
<CONT_DATA CI_END="8.17862826605045" CI_START="1.8213717339495488" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="19.8" MEAN_2="14.8" MODIFIED="2014-11-15 18:01:48 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="68" SD_1="7.8" SD_2="4.4" SE="1.6217789159000193" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" WEIGHT="23.72380253409877"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.851365868405207" CI_END="-1.4403691399872107" CI_START="-5.218774034009067" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.329571586998139" ESTIMABLE="YES" I2="41.61748070635323" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2015-01-21 14:33:03 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="4" P_CHI2="0.1439545911883966" P_Q="1.0" P_Z="5.517575107600539E-4" Q="0.0" RANDOM="YES" SCALE="72.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.5405093489852186" TOTALS="YES" TOTAL_1="346" TOTAL_2="347" UNITS="" WEIGHT="99.99999999999999" Z="3.454283263707034">
<NAME>Length of hospital stay (Selenium)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.40954338633002" CI_START="-13.40954338633002" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="38.5" MEAN_2="39.5" MODIFIED="2014-11-15 18:09:59 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="70" SD_1="24.4" SD_2="15.7" SE="6.331516029995915" STUDY_ID="STD-Angstwurm-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.2318703539323996"/>
<CONT_DATA CI_END="71.16861124611046" CI_START="-30.76861124611046" EFFECT_SIZE="20.200000000000003" ESTIMABLE="YES" MEAN_1="83.0" MEAN_2="62.8" MODIFIED="2014-11-15 18:10:13 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="74" SD_1="73.5" SD_2="30.2" SE="26.00487133852681" STUDY_ID="STD-Berger-2001" TOTAL_1="9" TOTAL_2="12" WEIGHT="0.13707656016141453"/>
<CONT_DATA CI_END="6.9140534215093385" CI_START="-8.314053421509337" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="31.3" MEAN_2="32.0" MODIFIED="2014-11-15 18:10:32 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="71" SD_1="18.0" SD_2="11.6" SE="3.884792517397268" STUDY_ID="STD-Forceville-2007" TOTAL_1="31" TOTAL_2="29" WEIGHT="5.586157138853887"/>
<CONT_DATA CI_END="-3.8940311314719427" CI_START="-5.105968868528057" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="17.0" MODIFIED="2014-11-15 18:10:49 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="72" SD_1="0.6" SD_2="1.7" SE="0.30917347120042116" STUDY_ID="STD-Montoya-2009" TOTAL_1="34" TOTAL_2="34" WEIGHT="56.787351406306094"/>
<CONT_DATA CI_END="-0.04936680114878733" CI_START="-4.150633198851208" EFFECT_SIZE="-2.099999999999998" ESTIMABLE="YES" MEAN_1="31.7" MEAN_2="33.8" MODIFIED="2014-11-15 18:11:10 +0000" MODIFIED_BY="Mikkel Allingstrup" ORDER="73" SD_1="11.0" SD_2="12.4" SE="1.0462606532703373" STUDY_ID="STD-SIGNET-2011" TOTAL_1="251" TOTAL_2="251" WEIGHT="35.257544540746196"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-27 13:22:02 +0100" MODIFIED_BY="Jane Cracknell">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for the updated review. (In the original article, <LINK REF="REF-Avenell-2004" TYPE="REFERENCE">Avenell 2004</LINK>, 10 studies were included and 11 studies were excluded with reasons. Three were awaiting classification, of which one has now been excluded (<LINK REF="STD-Kiessling-2006" TYPE="STUDY">Kiessling 2006</LINK>). Two studies are still ongoing).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqMAAAJKCAYAAAAY1EwiAABi/klEQVR42u2dD2RX3//HvyRJksh8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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-07-25 14:49:26 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXMAAAM1CAIAAAANRoadAAA4xUlEQVR42u2dsU4kO/aHS0JCBBMQ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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-07-25 06:27:07 +0100" MODIFIED_BY="Mikkel Allingstrup" NO="4" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1.2 Overall mortality (regardless of the follow-up period).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Dias1.jpg" FILE_TYPE="JPG" ID="FIG-05" MODIFIED="2015-07-27 13:22:02 +0100" MODIFIED_BY="Jane Cracknell" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis (TSA) of all trials examining the effect of Selenium supplementation on mortality among critically ill. Using a control event proportion of 32% found in the included trials, with a type 1 error of 5% and a 18% relative risk reduction (80% power), the trial sequential monitoring boundary for benefit is not crossed by the z-curve. However, these lines are very close to crossing each other which may indicate a probability of lack of random error for the conclusion of an effect of 18% relative risk reduction even though the required information size (N = 2605) has not yet been reached. However, caution must be exerted when interpreting the results of this TSA since all included studies are at high risk of bias and the intervention effect is likely to have been overestimated in the traditional meta-analysis.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">Cochrane Central Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>#1 MeSH descriptor: [Selenium] explode all trees<BR/>#2 MeSH descriptor: [Selenium Compounds] explode all trees<BR/>#3 selen* <BR/>#4 ebselen <BR/>#5 #1 or #2 or #3 or #4 <BR/>#6 #5 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2015-07-27 12:52:32 +0100" MODIFIED_BY="Jane Cracknell">MEDLINE (Ovid SP) and Healthstar search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>1. exp Selenium Compounds/ or exp Selenium/ or (selen* or ebselen*).mp.2. (randomized controlled trial.pt. or controlled clinical trial.pt.or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals.sh not (humans.sh and animals.sh))<BR/>3. 1 and 2<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-01-30 21:40:12 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-01-30 21:40:12 +0000" MODIFIED_BY="[Empty name]">EMBASE (Ovid SP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>1. exp selenium derivative/ or exp selenium/ or (selen* or ebselen*).ti,ab.<BR/>2. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab.) not (animals not (humans and animals)).sh.<BR/>3. 1 and 2</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-05-20 15:11:23 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="4">
<TITLE MODIFIED="2008-06-20 22:46:34 +0100" MODIFIED_BY="Karen Hovhannisyan">CAB abstracts search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-20 22:49:26 +0100" MODIFIED_BY="Karen Hovhannisyan">
<P>1. random$.tw<BR/>2. trials$.tw<BR/>3. placebo$.tw<BR/>4. 1 or 2 or 3<BR/>5. selen$.tw<BR/>6. ebselen.tw<BR/>7. 5 or 6<BR/>8. 4 and 7</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup" NO="5">
<TITLE MODIFIED="2008-06-20 22:46:47 +0100" MODIFIED_BY="Karen Hovhannisyan">BIOSIS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>#1 TI=selen* or TI=ebselen*<BR/>#2 TS=(random* or trial* or placebo*)<BR/>#3 #1 and #2</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2015-01-30 21:40:27 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2015-01-30 21:40:27 +0000" MODIFIED_BY="[Empty name]">CINAHL (EBSCOhost) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-30 11:55:14 +0000" MODIFIED_BY="Mikkel Allingstrup">
<P>S1 ((MM "Selenium") OR (MM "Selenium Compounds")) or selen* or ebselen*<BR/>S2 random* or ((clinical or controlled) N3 trials) or placebo* or multicenter or prospective or ((blind* or mask*) N3 (single or double or triple or treble))<BR/>S3 S1 and S2</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 studies are the basis for this new meta-analysis&lt;/p&gt;" WIDTH="321">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 new studies included in this updated quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="166">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included for full-text assessment&lt;/p&gt;" WIDTH="148">
<FLOWCHARTBOX TEXT="&lt;p&gt;36 studies assessed by abstract reading&lt;/p&gt;" WIDTH="135">
<FLOWCHARTBOX TEXT="&lt;p&gt;1330 records screened&lt;/p&gt;" WIDTH="149">
<FLOWCHARTBOX TEXT="&lt;p&gt;1325 records identified through database searching&lt;/p&gt;" WIDTH="127"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;5 additional records identified through handsearching&lt;/p&gt;" WIDTH="129"/>
<OUT TEXT="&lt;p&gt;1294 records excluded&lt;/p&gt;" WIDTH="146"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;25 articles excluded&lt;/p&gt;" WIDTH="130"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;5 articles excluded, with reasons (&lt;a link_type=&quot;STUDY&quot; href=&quot;Berger 2008&quot; protected=&quot;true&quot;&gt;Berger 2008&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Collier 2008&quot; protected=&quot;true&quot;&gt;Collier 2008&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Kiessling 2006&quot; protected=&quot;true&quot;&gt;Kiessling 2006&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;REDOXS 2011&quot; protected=&quot;true&quot;&gt;REDOXS 2011&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Stoppe 2010&quot; protected=&quot;true&quot;&gt;Stoppe 2010&lt;/a&gt;)&lt;/p&gt;" WIDTH="189"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in the original quantitative synthesis (&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Avenell 2004&quot; protected=&quot;true&quot;&gt;Avenell 2004&lt;/a&gt;)&lt;/p&gt;" WIDTH="144"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>